Biography
Clinical Focus: Cardiovascular Medicine: Atrial Fibrillation; Chronic CAD; ACS;
Research Focus:
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Associate Dean, Clinical Research School of Medicine; Vice Chair of Clinical Research Department of Medicine; Director Stanford Center for Clinical Research; Member of the Stanford IRB
Professional Training:
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Faculty Cardiovascular Medicine
Research Focus:
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Associate Dean, Clinical Research School of Medicine; Vice Chair of Clinical Research Department of Medicine; Director Stanford Center for Clinical Research; Member of the Stanford IRB
Professional Training:
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Faculty Cardiovascular Medicine
View Full Biography
Professional Summary
Education & Certifications
- Fellowship: Duke University (1996) NC
- Residency: University of Arizona Internal Medicine Residency (1993) AZ
- Medical Education: University of Washington Medical Center (1989) WA
-
- Board Certification: American Board of Internal Medicine, Cardiovascular Disease (1997)
Memberships
- Editorial Board Member, Current Cardiology Reviews (2004 - Present)
- Associate Editor, American Heart Journal (2005 - Present)
- Editorial Board Member, Current Cardiology Reports (2012 - Present)
-
- Editorial Board Member, Cardiology & Therapy Journal (2012 - Present)
Administrative Appointments
- Member, Stanford Diabetes Research Center (2017 - Present)
- Steering Committee Member, Department of Medicine Team Science Initiative, Department of Medicine (2022 - Present)
- Vice Chair of Clinical Research, Department of Medicine (2013 - Present)
-
Publications
-
Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): Rationale and design overview
Chertow, G. M., Pupim, L. B., Block, G. A., Correa-Rotter, R., Drueke, T. B., Floege, J., … Parfrey, P. (2007). Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): Rationale and design overview. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2(5), 898–905. -
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease - A randomized trial
Stone, G. W., Midei, M., Newman, W., Sanz, M., Hermiller, J. B., Williams, J., … Lansky, A. J. (2008). Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease - A randomized trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 299(16), 1903–13. -
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., … Harrington, R. A. (2009). Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. NEW ENGLAND JOURNAL OF MEDICINE, 361(11), 1045–1057. -
-
Comparison of Site-Reported and Core Laboratory-Reported Creatine Kinase-MB Values in Non-ST-Segment Elevation Acute Coronary Syndrome (from the International Trial SYNERGY)
Linefsky, J. P., Lin, M., Pieper, K. S., Reist, C. J., Berdan, L. G., Antman, E. M., … Mahaffey, K. W. (2009). Comparison of Site-Reported and Core Laboratory-Reported Creatine Kinase-MB Values in Non-ST-Segment Elevation Acute Coronary Syndrome (from the International Trial SYNERGY). AMERICAN JOURNAL OF CARDIOLOGY, 104(10), 1330–1335. -
Platelet Inhibition with Cangrelor in Patients Undergoing PCI.
Harrington, R. A., Stone, G. W., McNulty, S., White, H. D., Lincoff, A. M., Gibson, C. M., … Bhatt, D. L. (2009). Platelet Inhibition with Cangrelor in Patients Undergoing PCI. NEW ENGLAND JOURNAL OF MEDICINE, 361(24), 2318–2329. -
Intravenous Platelet Blockade with Cangrelor during PCI.
Bhatt, D. L., Lincoff, A. M., Gibson, C. M., Stone, G. W., McNulty, S., Montalescot, G., … Harrington, R. A. (2009). Intravenous Platelet Blockade with Cangrelor during PCI. NEW ENGLAND JOURNAL OF MEDICINE, 361(24), 2330–2341. -
Warfarin Use and Outcomes in Patients with Atrial Fibrillation Complicating Acute Coronary Syndromes
Lopes, R. D., Starr, A., Pieper, C. F., Al-Khatib, S. M., Newby, L. K., Mehta, R. H., … Granger, C. B. (2010). Warfarin Use and Outcomes in Patients with Atrial Fibrillation Complicating Acute Coronary Syndromes. AMERICAN JOURNAL OF MEDICINE, 123(2), 134–140. -
Influence of clinical trial participation on subsequent antithrombin use.
Shah, B. R., Peterson, E. D., Chen, A. Y., Mahaffey, K. W., DeLong, E. R., Ohman, E. M., … Roe, M. T. (2010). Influence of clinical trial participation on subsequent antithrombin use. Clinical Cardiology, 33(3), E49–55. -
An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481-The Home INR Study (THINRS)
Dolor, R. J., Ruybalid, R. L., Uyeda, L., Edson, R. G., Phibbs, C., Vertrees, J. E., … Matchar, D. B. (2010). An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481-The Home INR Study (THINRS). JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 30(3), 263–75. -
Effect of Home Testing of International Normalized Ratio on Clinical Events.
Matchar, D. B., Jacobson, A., Dolor, R., Edson, R., Uyeda, L., Phibbs, C. S., … Lavori, P. (2010). Effect of Home Testing of International Normalized Ratio on Clinical Events. NEW ENGLAND JOURNAL OF MEDICINE, 363(17), 1608–20. -
Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: A pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY
Chan, M. Y., Sun, J. L., Wang, T. Y., Lopes, R. D., Jolicoeur, M. E., Pieper, K. S., … Peterson, E. D. (2010). Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: A pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. AMERICAN HEART JOURNAL, 160(6), 1056–U95. -
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial
Held, C., Asenblad, N., Bassand, J. P., Becker, R. C., Cannon, C. P., Claeys, M. J., … Wallentin, L. (2011). Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 57(6), 672–684. -
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, Sao Paulo, Brazil
Lopes, R. D., Becker, R. C., Alexander, J. H., Armstrong, P. W., Califf, R. M., Chan, M. Y., … Garcia, D. A. (2011). Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, Sao Paulo, Brazil. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 32(2), 242–266. -
Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Mahaffey, K. W., Wojdyla, D. M., Carroll, K., Becker, R. C., Storey, R. F., Angiolillo, D. J., … Wallentin, L. (2011). Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION, 124(5), 544–U78. -
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., Van de Werf, F., … Mahaffey, K. W. (2012). Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. NEW ENGLAND JOURNAL OF MEDICINE, 366(1), 20–33. -
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial
Becker, R. C., Bassand, J. P., Budaj, A., Wojdyla, D. M., James, S. K., Cornel, J. H., … Wallentin, L. (2011). Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. EUROPEAN HEART JOURNAL, 32(23), 2933–2944. -
Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor Insights From the Platelet Inhibition and Patient Outcomes Trial
Goodman, S. G., Clare, R., Pieper, K. S., Nicolau, J. C., Storey, R. F., Cantor, W. J., … Wallentin, L. (2012). Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor Insights From the Platelet Inhibition and Patient Outcomes Trial. CIRCULATION, 125(8), 978–986. -
Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction
White, H. D., Chew, D. P., Dauerman, H. L., Mahaffey, K. W., Gibson, C. M., Stone, G. W., … Bhatt, D. L. (2012). Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. AMERICAN HEART JOURNAL, 163(2), 182–U275. -
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years
Chan, M. Y., Sun, J.-L., Newby, L. K., Lokhnygina, Y., White, H. D., Moliterno, D. J., … Harrington, R. A. (2013). Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. INTERNATIONAL JOURNAL OF CARDIOLOGY, 167(2), 548–554. -
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial
Chertow, G. M., Correa-Rotter, R., Block, G. A., Drueke, T. B., Floege, J., Goodman, W. G., … Parfrey, P. S. (2012). Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. NEPHROLOGY DIALYSIS TRANSPLANTATION, 27(7), 2872–79. -
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial
Leonardi, S., Mahaffey, K. W., White, H. D., Gibson, C. M., Stone, G. W., Steg, P. G. W., … Bhatt, D. L. (2012). Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. AMERICAN HEART JOURNAL, 163(5), 768-? -
Venous Thromboembolism Yet Another Cardiovascular Complication of Chronic Kidney Disease?
Chertow, G. M., & Mahaffey, K. W. (2012). Venous Thromboembolism Yet Another Cardiovascular Complication of Chronic Kidney Disease? CIRCULATION, 126(16), 1937–38. -
A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial
Leonardi, S., Truffa, A. A., Neely, M. L., Tricoci, P., White, H. D., Gibson, C. M., … Mahaffey, K. W. (2013). A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. HEART, 99(17), 1282–87. -
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Bhatt, D. L., Stone, G. W., Mahaffey, K. W., Gibson, C. M., Steg, P. G., Hamm, C. W., … Harrington, R. A. (2013). Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. NEW ENGLAND JOURNAL OF MEDICINE, 368(14), 1303–13. -
Left Bundle Branch Block in Non-ST-Segment Elevation Acute Coronary Syndromes Incidence, Angiographic Characteristics, and Clinical Outcomes
Rose, J. J., Newby, L. K., Broderick, S., Chiswell, K., Van de Werf, F., Armstrong, P. W., … Lopes, R. D. (2013). Left Bundle Branch Block in Non-ST-Segment Elevation Acute Coronary Syndromes Incidence, Angiographic Characteristics, and Clinical Outcomes. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 61(13), 1461–1463. -
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA.CER) trial
Leonardi, S., Tricoci, P., White, H. D., Armstrong, P. W., Huang, Z., Wallentin, L., … Mahaffey, K. W. (2013). Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA.CER) trial. EUROPEAN HEART JOURNAL, 34(23), 1723–1731. -
Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends
Tricoci, P., Leonardi, S., White, J., White, H. D., Armstrong, P. W., Montalescot, G., … Newby, L. K. (2013). Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 62(3), 242–51. -
Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis
Chertow, G. M., Block, G. A., Correa-Rotter, R., Drueeke, T. B., Floege, J., Goodman, W. G., … Parfrey, P. S. (2012). Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. NEW ENGLAND JOURNAL OF MEDICINE, 367(26), 2482–94. -
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.
Chertow, G. M., Block, G. A., Correa-Rotter, R., Drüeke, T. B., Floege, J., Goodman, W. G., … Parfrey, P. S. (2012). Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. New England Journal of Medicine, 367(26), 2482–2494. -
Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation
Hess, P. L., Kim, S., Piccini, J. P., Allen, L. A., Ansell, J. E., Chang, P., … Fonarow, G. C. (2013). Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation. AMERICAN JOURNAL OF MEDICINE, 126(7), 625-? -
Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial
Steg, P. G., Harrington, R. A., Emanuelsson, H., Katus, H. A., Mahaffey, K. W., Meier, B., … James, S. K. (2013). Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial. CIRCULATION, 128(10), 1055–65. -
The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial
Parfrey, P. S., Chertow, G. M., Block, G. A., Correa-Rotter, R., Drueeke, T. B., Floege, J., … Goodman, W. G. (2013). The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 98(12), 4834–44. -
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
Steg, P. G., Bhatt, D. L., Hamm, C. W., Stone, G. W., Gibson, C. M., Mahaffey, K. W., … Harrington, R. A. (2013). Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. LANCET, 382(9909), 1981–92. -
Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
Steinberg, B. A., Holmes, D. J. N., Piccini, J. P., Ansell, J., Chang, P., Fonarow, G. C., … Hylek, E. M. (2013). Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2(6). -
Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial
Wallentin, L., Lindholm, D., Siegbahn, A., Wernroth, L., Becker, R. C., Cannon, C. P., … James, S. K. (2014). Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION, 129(3), 293–303. -
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Mahaffey, K. W., Stevens, S. R., White, H. D., Nessel, C. C., Goodman, S. G., Piccini, J. P., … Breithardt, G. (2014). Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. European Heart Journal, 35(4), 233–41. -
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention: Insights From the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).
Généreux, P., Stone, G. W., Harrington, R. A., Gibson, C. M., Steg, P. G., Brener, S. J., … Bhatt, D. L. (2014). Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention: Insights From the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). Journal of the American College of Cardiology, 63(7), 619–29. -
Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial).
Mahaffey, K. W., Huang, Z., Wallentin, L., Storey, R. F., Jennings, L. K., Tricoci, P., … Harrington, R. A. (2014). Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). American Journal of Cardiology, 113(6), 936–44. -
Heart Failure Complicating Non-ST-Segment Elevation Acute Coronary Syndrome: Timing, Predictors, and Clinical Outcomes.
Bahit, M. C., Lopes, R. D., Clare, R. M., Newby, L. K., Pieper, K. S., Van de Werf, F., … Granger, C. B. (2013). Heart Failure Complicating Non-ST-Segment Elevation Acute Coronary Syndrome: Timing, Predictors, and Clinical Outcomes. JACC. Heart Failure, 1(3), 223–29. -
Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery: Subgroup Analysis From the TRACER Trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
Whellan, D. J., Tricoci, P., Chen, E., Huang, Z., Leibowitz, D., Vranckx, P., … Mahaffey, K. W. (2014). Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery: Subgroup Analysis From the TRACER Trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). Journal of the American College of Cardiology, 63(11), 1048–57. -
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
O'Brien, E. C., Holmes, D. J. N., Ansell, J. E., Allen, L. A., Hylek, E., Kowey, P. R., … Singer, D. E. (2014). Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. American Heart Journal, 167(4), 601–9 e1. -
Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Mahaffey, K. W., Held, C., Wojdyla, D. M., James, S. K., Katus, H. A., Husted, S., … Wallentin, L. (2014). Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. Journal of the American College of Cardiology, 63(15), 1493–99. -
Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
Steinberg, B. A., Kim, S., Fonarow, G. C., Thomas, L., Ansell, J., Kowey, P. R., … Piccini, J. P. (2014). Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 167(5), 735–42 e2. -
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Hankey, G. J., Stevens, S. R., Piccini, J. P., Lokhnygina, Y., Mahaffey, K. W., Halperin, J. L., … Califf, R. M. (2014). Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke; a Journal of Cerebral Circulation, 45(5), 1304–12. -
Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
Steinberg, B. A., Kim, S., Thomas, L., Fonarow, G. C., Hylek, E., Ansell, J., … Peterson, E. D. (2014). Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation, 129(20), 2005–12. -
Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Results From the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Sherwood, M. W., Douketis, J. D., Patel, M. R., Piccini, J. P., Hellkamp, A. S., Lokhnygina, Y., … Becker, R. C. (2014). Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Results From the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation, 129(18), 1850–59. -
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial.
Steinberg, B. A., Hellkamp, A. S., Lokhnygina, Y., Halperin, J. L., Breithardt, G., Passman, R., … Piccini, J. P. (2014). Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm , 11(6), 925–32. -
Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Steinberg, B. A., Kim, S., Fonarow, G. C., Thomas, L., Ansell, J., Kowey, P. R., … Piccini, J. P. (2014). Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). AMERICAN HEART JOURNAL, 167(5), 735–U131. -
Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis
Mahaffey, K. W., Wojdyla, D. M., Pieper, K. S., Tricoci, P., Alexander, J. H., Lincoff, A. M., … Harrington, R. A. (2014). Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis. CLINICAL CARDIOLOGY, 37(6), 337–42. -
Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Halperin, J. L., Hankey, G. J., Wojdyla, D. M., Piccini, J. P., Lokhnygina, Y., Patel, M. R., … Fox, K. A. A. (2014). Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). CIRCULATION, 130(2), 138–U45. -
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
O'Brien, E. C., Holmes, D. J. N., Ansell, J. E., Allen, L. A., Hylek, E., Kowey, P. R., … Singer, D. E. (2014). Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. AMERICAN HEART JOURNAL, 167(4), 601–U229. -
Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Steinberg, B. A., Kim, S., Thomas, L., Fonarow, G. C., Hylek, E., Ansell, J., … Peterson, E. D. (2014). Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation, 129(20), 2005–12. -
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013.
Wallentin, L., Becker, R. C., Cannon, C. P., Held, C., Himmelmann, A., Husted, S., … Harrington, R. A. (2014). Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. International Journal of Cardiology, 170(3), e59–62. -
Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis.
Mahaffey, K. W., Wojdyla, D. M., Pieper, K. S., Tricoci, P., Alexander, J. H., Lincoff, A. M., … Harrington, R. A. (2014). Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis. Clinical Cardiology, 37(6), 337–42. -
Independent data monitoring committees: Preparing a path for the future.
Hess, C. N., Roe, M. T., Gibson, C. M., J Temple, R., Pencina, M. J., Zarin, D. A., … Califf, R. M. (2014). Independent data monitoring committees: Preparing a path for the future. American Heart Journal, 168(2), 135–41 e1. -
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
Piccini, J. P., Garg, J., Patel, M. R., Lokhnygina, Y., Goodman, S. G., Becker, R. C., … Fox, K. A. A. (2014). Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. European Heart Journal, 35(28), 1873–80. -
Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment.
Cryer, B., & Mahaffey, K. W. (2014). Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. Journal of Multidisciplinary Healthcare, 7, 137–46. -
Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER.
White, H. D., Huang, Z., Tricoci, P., Van de Werf, F., Wallentin, L., Lokhnygina, Y., … Armstrong, P. W. (2014). Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER. Journal of the American Heart Association, 3(4). -
Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry.
Steinberg, B. A., Blanco, R. G., Ollis, D., Kim, S., Holmes, D. J. N., Kowey, P. R., … Piccini, J. P. (2014). Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry. American Heart Journal, 168(2), 160–67. -
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin, J. L., Hankey, G. J., Wojdyla, D. M., Piccini, J. P., Lokhnygina, Y., Patel, M. R., … Fox, K. A. A. (2014). Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation, 130(2), 138–46. -
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.
Held, C., Tricoci, P., Huang, Z., Van de Werf, F., White, H. D., Armstrong, P. W., … Mahaffey, K. W. (2014). Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. European Heart Journal. Acute Cardiovascular Care, 3(3), 246–56. -
Challenges and solutions to pre- and post-randomization subgroup analyses.
Desai, M., Pieper, K. S., & Mahaffey, K. (2014). Challenges and solutions to pre- and post-randomization subgroup analyses. Current Cardiology Reports, 16(10), 531-? -
Usefulness and Safety of Vorapaxar in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial).
Valgimigli, M., Tricoci, P., Huang, Z., Aylward, P. E., Armstrong, P. W., Van de Werf, F., … Moliterno, D. J. (2014). Usefulness and Safety of Vorapaxar in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial). American Journal of Cardiology, 114(5), 665–73. -
Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
O'Brien, E. C., Simon, D. J. N., Allen, L. A., Singer, D. E., Fonarow, G. C., Kowey, P. R., … Peterson, E. D. (2014). Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). AMERICAN HEART JOURNAL, 168(4), 487–94. -
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)
Jones, W. S., Tricoci, P., Huang, Z., Moliterno, D. J., Harrington, R. A., Sinnaeve, P. R., … Mahaffey, K. W. (2014). Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). AMERICAN HEART JOURNAL, 168(4), 588–96. -
Challenges and Priorities for Research A Report From the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on Thrombosis in Pediatric Cardiology and Congenital Heart Disease
McCrindle, B. W., Li, J. S., Manlhiot, C., Tweddell, J. S., Giglia, T. M., Massicotte, M. P., … Kaltman, J. R. (2014). Challenges and Priorities for Research A Report From the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on Thrombosis in Pediatric Cardiology and Congenital Heart Disease. CIRCULATION, 130(14), 1192–1203. -
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
Wheeler, D. C., London, G. M., Parfrey, P. S., Block, G. A., Correa-Rotter, R., Dehmel, B., … Herzog, C. A. (2014). Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. Journal of the American Heart Association, 3(6). -
Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial
Wheeler, D. C., London, G. M., Parfrey, P. S., Block, G. A., Correa-Rotter, R., Dehmel, B., … Herzog, C. A. (2014). Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 3(6). -
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Schwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., … Steg, P. G. (2014). Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. AMERICAN HEART JOURNAL, 168(5), 682–89. -
Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes
Varenhorst, C., Alstrom, U., Braun, O. O., Storey, R. F., Mahaffey, K. W., Bertilsson, M., … Held, C. (2014). Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. HEART, 100(22), 1762-? -
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
Tricoci, P., Lokhnygina, Y., Huang, Z., Van de Werf, F., Cornel, J. H., Chen, E., … Mahaffey, K. W. (2014). Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial. AMERICAN HEART JOURNAL, 168(6), 869-? -
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
Breithardt, G., Baumgartner, H., Berkowitz, S. D., Hellkamp, A. S., Piccini, J. P., Stevens, S. R., … Califf, R. M. (2014). Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. EUROPEAN HEART JOURNAL, 35(47), 3377–85. -
Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
Steinberg, B. A., Peterson, E. D., Kim, S., Thomas, L., Gersh, B. J., Fonarow, G. C., … Ansell, J. (2015). Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation, 131(5), 488–94. -
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
Steinberg, B. A., Hellkamp, A. S., Lokhnygina, Y., Patel, M. R., Breithardt, G., Hankey, G. J., … Piccini, J. P. (2015). Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. European Heart Journal, 36(5), 288–96. -
Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium
Seltzer, J. H., Turner, J. R., Geiger, M. J., Rosano, G., Mahaffey, K. W., White, W. B., … Sager, P. T. (2015). Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium. AMERICAN HEART JOURNAL, 169(2), 197–204. -
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Ways, K., … Matthews, D. (2015). Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care, 38(3), 403–11. -
Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial
Wheeler, D. C., London, G. M., Parfrey, P. S., Block, G. A., Correa-Rotter, R., Dehmel, B., … Herzog, C. A. (2015). Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 4(1). -
Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial.
Singer, D. E., Hellkamp, A. S., Yuan, Z., Lokhnygina, Y., Patel, M. R., Piccini, J. P., … Califf, R. M. (2015). Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial. Journal of the American Heart Association, 4(3). -
Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin Insights From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])
White, H. D., Bhatt, D. L., Gibson, C. M., Hamm, C. W., Mahaffey, K. W., Price, M. J., … Harrington, R. A. (2015). Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin Insights From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC-CARDIOVASCULAR INTERVENTIONS, 8(3), 424–33. -
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., … Tomaselli, G. F. (2010). ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. AMERICAN JOURNAL OF GASTROENTEROLOGY, 105(12), 2533–2549. -
Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE initiative
Singh, K. P., Roe, M. T., Peterson, E. D., Chen, A. Y., Mahaffey, K. W., Goodman, S. G., … Pollack, C. V. (2006). Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE initiative. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 21(3), 211–220. -
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal
Cantor, W. J., Mahaffey, K. W., Huang, Z., Das, P., Gulba, D. C., Glezer, S., … Goodman, S. G. (2007). Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 69(1), 73–83. -
Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial
Tcheng, J. E., O'Shea, J. C., Cohen, E. A., Pacchiana, C. M., Kitt, M. M., Lorenz, T. J., … Veltri, E. (2000). Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. LANCET, 356(9247), 2037–44. -
Factors Associated With Major Bleeding Events
Goodman, S. G., Wojdyla, D. M., Piccini, J. P., White, H. D., Paolini, J. F., Nessel, C. C., … Califf, R. M. (2014). Factors Associated With Major Bleeding Events. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 63(9), 891–900. -
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes
Storey, R. F., Kotha, J., Smyth, S. S., Moliterno, D. J., Rorick, T. L., Moccetti, T., … Jennings, L. K. (2014). Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. THROMBOSIS AND HAEMOSTASIS, 111(5), 883–891. -
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention
Tardiff, B. E., Califf, R. M., Tcheng, J. E., Lincoff, A. M., Sigmon, K. N., Harrington, R. A., … Topol, E. J. (1999). Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 33(1), 88–96. -
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
White, H. D., Held, C., Stewart, R., Tarka, E., Brown, R., Davies, R. Y., … Wallentin, L. (2014). Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. NEW ENGLAND JOURNAL OF MEDICINE, 370(18), 1702–11. -
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials
Mahaffey, K. W., Roe, M. T., Kilaru, R., Alexander, J. H., Van de Werf, F., Califf, R. M., … Harrington, R. A. (2007). Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. EUROPEAN HEART JOURNAL, 28(4), 425–432. -
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome
Leung, S., Gallup, D., Mahaffey, K. W., Cohen, M., Antman, E. M., Goodman, S. G., … Califf, R. M. (2008). Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. AMERICAN HEART JOURNAL, 156(1), 177–184. -
Stroke in patients with acute coronary syndromes - Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial
Mahaffey, K. W., Harrington, R. A., Simoons, M. L., Granger, C. B., Graffagnino, C., Alberts, M. J., … Califf, R. M. (1999). Stroke in patients with acute coronary syndromes - Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial. CIRCULATION, 99(18), 2371–2377. -
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial: study design and rationale
Harrington, R. A., Van de Werf, F., Armstrong, P. W., Aylward, P., Veltri, E., Mahaffey, K. W., … Whellan, D. (2009). The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial: study design and rationale. AMERICAN HEART JOURNAL, 158(3), 327–U5. -
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients
Kaul, P., Newby, L. K., Fu, Y. L., Hasselblad, V., Mahaffey, K. W., Christenson, R. H., … Armstrong, P. W. (2003). Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 41(3), 371–80. -
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes - A systematic overview
Petersen, J. L., Mahaffey, K. W., Hasselblad, V., Antman, E. M., Cohen, M., Goodman, S. G., … Califf, R. M. (2004). Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes - A systematic overview. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 292(1), 89–96. -
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes
Mahaffey, K. W., Roe, M. T., Kilaru, R., French, J. K., Alexander, J. H., Berdan, L. G., … Harrington, R. A. (2005). Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. AMERICAN JOURNAL OF CARDIOLOGY, 95(12), 1404–1408. -
Time to coronary angiography and outcomes among patients with high-risk non-ST-segment-elevation acute coronary syndromes: Results from the SYNERGY trial
Tricoci, P., Lokhnygina, Y., Berdan, L. G., Steinhubl, S. R., Gulba, D. C., White, H. D., … Mahaffey, K. W. (2007). Time to coronary angiography and outcomes among patients with high-risk non-ST-segment-elevation acute coronary syndromes: Results from the SYNERGY trial. CIRCULATION, 116(23), 2669–2677. -
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes
Roe, M. T., Mahaffey, K. W., Kilaru, R., Alexander, J. H., Akkerhuis, K. M., Simoons, M. L., … Topol, E. J. (2004). Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. EUROPEAN HEART JOURNAL, 25(4), 313–321. -
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Parfrey, P. S., Drueeke, T. B., Block, G. A., Correa-Rotter, R., Floege, J., Herzog, C. A., … Chertow, G. M. (2015). The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 10(5), 791–99. -
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
Moe, S. M., Abdalla, S., Chertow, G. M., Parfrey, P. S., Block, G. A., Correa-Rotter, R., … Drüeke, T. B. (2015). Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Journal of the American Society of Nephrology , 26(6), 1466–75. -
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Parfrey, P. S., Drüeke, T. B., Block, G. A., Correa-Rotter, R., Floege, J., Herzog, C. A., … Chertow, G. M. (2015). The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clinical Journal of the American Society of Nephrology , 10(5), 791–99. -
The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations
Roe, M. T., Mahaffey, K. W., Ezekowitz, J. A., Alexander, J. H., Goodman, S. G., Hernandez, A., … Armstrong, P. W. (2015). The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. AMERICAN HEART JOURNAL, 169(6), 743–50. -
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)
Cornel, J. H., Tricoci, P., Lokhnygina, Y., Moliterno, D. J., Wallentin, L., Armstrong, P. W., … Harrington, R. A. (2015). Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). AMERICAN JOURNAL OF CARDIOLOGY, 115(10), 1325–32. -
Promises of PAR-1 Inhibition in Acute Coronary Syndrome
Leonardi, S., Tricoci, P., & Mahaffey, K. W. (2012). Promises of PAR-1 Inhibition in Acute Coronary Syndrome. CURRENT CARDIOLOGY REPORTS, 14(1). -
Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial
Mahaffey, K. W., Roe, M. T., Dyke, C. K., Newby, L. K., Kleiman, N. S., Connolly, P., … Harrington, R. A. (2002). Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial. AMERICAN HEART JOURNAL, 143(2), 242–248. -
Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil
Lopes, R. D., Becker, R. C., Newby, L. K., Peterson, E. D., Hylek, E. M., Giugliano, R., … Garcia, D. A. (2013). Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 36(1), 115–130. -
Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study
Mahaffey, K. W., Harrington, R. A., Akkerhuis, M., Kleiman, N. S., Berdan, L. G., Crenshaw, B. S., … Califf, R. M. (2001). Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2(4), 187–194. -
Systematic adjudication of myocardial infarction end-points in an international clinical trial
Mahaffey, K. W., Harrington, R. A., Akkerhuis, M., Kleiman, N. S., Berdan, L. G., Crenshaw, B. S., … Califf, R. M. (2001). Systematic adjudication of myocardial infarction end-points in an international clinical trial. CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2(4), 180–186. -
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Moe, S. M., Chertow, G. M., Parfrey, P. S., Kubo, Y., Block, G. A., Correa-Rotter, R., … Floege, J. (2015). Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. CIRCULATION, 132(1), 27–39. -
Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial
Kubo, Y., Sterling, L. R., Parfrey, P. S., Gill, K., Mahaffey, K. W., Gioni, I., … Chertow, G. M. (2015). Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial. PHARMACEUTICAL STATISTICS, 14(3), 242–51. -
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Moe, S. M., Chertow, G. M., Parfrey, P. S., Kubo, Y., Block, G. A., Correa-Rotter, R., … Floege, J. (2015). Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation, 132(1), 27–39. -
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Stein, P., … Matthews, D. (2013). Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial. AMERICAN HEART JOURNAL, 166(2), 217-? -
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial
Patel, M. R., Becker, R. C., Wojdyla, D. M., Emanuelsson, H., Hiatt, W. R., Horrow, J., … James, S. K. (2015). Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 22(6), 734–42. -
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Washam, J. B., Stevens, S. R., Lokhnygina, Y., Halperin, J. L., Breithardt, G., Singer, D. E., … Patel, M. R. (2015). Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). LANCET, 385(9985), 2363–70. -
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
White, H. D., Kleiman, N. S., Mahaffey, K. W., Lokhnygina, Y., Pieper, K. S., Chiswell, K., … Califf, R. M. (2006). Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. AMERICAN HEART JOURNAL, 152(6), 1042–50. -
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes
Rao, S. V., O'Grady, K., Pieper, K. S., Granger, C. B., Newby, L. K., Van de Werf, F., … Harrington, R. A. (2005). Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. AMERICAN JOURNAL OF CARDIOLOGY, 96(9), 1200–1206. -
Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
Steinberg, B. A., Holmes, D. J. N., Ezekowitz, M. D., Fonarow, G. C., Kowey, P. R., Mahaffey, K. W., … Piccini, J. P. (2013). Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. AMERICAN HEART JOURNAL, 165(4), 622–629. -
Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade
Levine, G. N., Lincoff, A. M., Ferguson, J. J., Mahaffey, K. W., Goodman, S. G., Cannon, C. P., … Fox, K. A. A. (2005). Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 66(2), 149–157. -
Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
Patel, M. R., Hellkamp, A. S., Lokhnygina, Y., Piccini, J. P., Zhang, Z., Mohanty, S., … Mahaffey, K. W. (2013). Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 61(6), 651–658. -
Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts"
Piccini, J. P., Stevens, S. R., Chang, Y., Singer, D. E., Lokhnygina, Y., Go, A. S., … Califf, R. M. (2013). Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts". CIRCULATION, 128(11), E172–E173. -
Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction
Turer, A. T., Mahaffey, K. W., Gallup, D., Weaver, W. D., Christenson, R. H., Every, N. R., & Ohman, E. M. (2005). Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 6. -
Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease
Chan, M. Y., Mahaffey, K. W., Sun, L. J., Pieper, K. S., White, H. D., Aylward, P. E., … Roe, M. T. (2008). Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease. JACC-CARDIOVASCULAR INTERVENTIONS, 1(4), 369–378. -
Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts
Piccini, J. P., Stevens, S. R., Chang, Y., Singer, D. E., Lokhnygina, Y., Go, A. S., … Califf, R. M. (2013). Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts. CIRCULATION, 127(2), 224-? -
Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry
Steinberg, B. A., Kim, S., Piccini, J. P., Fonarow, G. C., Lopes, R. D., Thomas, L., … Peterson, E. D. (2013). Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. CIRCULATION, 128(7), 721–728. -
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin - Outcomes at 6 months and 1 year in the SYNERGY trial
Mahaffey, K. W., Cohen, M., Garg, J., Antman, E., Kleiman, N. S., Goodman, S. G., … Califf, R. M. (2005). High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin - Outcomes at 6 months and 1 year in the SYNERGY trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 294(20), 2594–2600. -
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation
Piccini, J. P., Lopes, R. D., & Mahaffey, K. W. (2010). Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. CURRENT OPINION IN CARDIOLOGY, 25(4), 312–320. -
Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention-Related Myocardial Infarction
Leonardi, S., Thomas, L., Neely, M. L., Tricoci, P., Lopes, R. D., White, H. D., … Mahaffey, K. W. (2012). Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention-Related Myocardial Infarction. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 60(22), 2296–2304. -
Prognostic Significance of Bleeding Location and Severity Among Patients With Acute Coronary Syndromes
Vavalle, J. P., Clare, R., Chiswell, K., Rao, S. V., Petersen, J. L., Kleiman, N. S., … Wang, T. Y. (2013). Prognostic Significance of Bleeding Location and Severity Among Patients With Acute Coronary Syndromes. JACC-CARDIOVASCULAR INTERVENTIONS, 6(7), 709–717. -
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome
Kassem-Moussa, H., Mahaffey, K. W., Graffagnino, C., Tasissa, G., Sila, C. A., Simes, R. J., … Newby, L. K. (2004). Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. AMERICAN HEART JOURNAL, 148(3), 439–446. -
Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial
Mahaffey, K. W., Tonev, S. T., Spinler, S. A., Levine, G. N., Gallo, R., Ducas, J., … Califf, R. M. (2010). Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial. INTERNATIONAL JOURNAL OF CARDIOLOGY, 139(2), 123–133. -
Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery
Varenhorst, C., Alstrom, U., Scirica, B. M., Hogue, C. W., Asenblad, N., Storey, R. F., … Held, C. (2012). Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 60(17), 1623–1630. -
Risks and Benefits of Anticoagulation in Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry
Cullen, M. W., Kim, S., Piccini, J. P., Ansell, J. E., Fonarow, G. C., Hylek, E. M., … Gersh, B. J. (2013). Risks and Benefits of Anticoagulation in Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 6(4), 461–469. -
Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry
Pokorney, S. D., Simon, D. J. N., Thomas, L., Fonarow, G. C., Kowey, P. R., Chang, P., … Peterson, E. D. (2015). Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. AMERICAN HEART JOURNAL, 170(1), 141–U194. -
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library
Petersen, J. L., Mahaffey, K. W., Becker, R. C., Goodman, S. G., Kleiman, N. S., Marian, A. J., … Ferguson, J. J. (2004). Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library. AMERICAN HEART JOURNAL, 148(2), 269–276. -
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
Becker, R. C., Moliterno, D. J., Jennings, L. K., Pieper, K. S., Pei, J., Niederman, A., … Harrington, R. A. (2009). Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. LANCET, 373(9667), 919–928. -
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients
Hess, C. N., Broderick, S., Piccini, J. P., Alexander, K. P., Newby, L. K., Shaw, L. K., … Lopes, R. D. (2012). Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. AMERICAN HEART JOURNAL, 164(4), 607–615. -
End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience
Mahaffey, K. W., Hellkamp, A. S., Patel, M. R., Hannan, K. L., Schwabe, K., Nessel, C. C., … Fox, K. A. A. (2013). End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 6(4), 470–478. -
Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels
Saw, J., Kereiakes, D. J., Mahaffey, K. W., Applegate, R. J., Braden, G. A., Brent, B. N., … Moliterno, D. J. (2003). Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. THROMBOSIS RESEARCH, 112(5-6), 301–306. -
Integrating ancillary studies in a large clinical trial: The design and rationale of the APEX library
Mahaffey, K. W., Reist, C. J., Fu, Y., Brener, S. J., Theroux, P., Patel, M. R., … Armstrong, P. W. (2008). Integrating ancillary studies in a large clinical trial: The design and rationale of the APEX library. CONTEMPORARY CLINICAL TRIALS, 29(6), 887–895. -
Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial
Husted, S., James, S., Becker, R. C., Horrow, J., Katus, H., Storey, R. F., … Wallentin, L. (2012). Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 5(5), 680–688. -
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Mahaffey, K. W., Hafley, G., Dickerson, S., Burns, S., Tourt-Uhlig, S., White, J., … Lopes, R. D. (2013). Results of a reevaluation of cardiovascular outcomes in the RECORD trial. AMERICAN HEART JOURNAL, 166(2), 240-? -
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes
Rebeiz, A. G., Roe, M. T., Alexander, J. H., Mahaffey, K. W., Granger, C. B., Peterson, E. D., … Harrington, R. A. (2004). Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. AMERICAN JOURNAL OF MEDICINE, 116(2), 119–129. -
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein Graft ENgineering via Transfection [PREVENT] IV)
Yau, J. M., Alexander, J. H., Hafley, G., Mahaffey, K. W., Mack, M. J., Kouchoukos, N., … Ferguson, T. B. (2008). Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein Graft ENgineering via Transfection [PREVENT] IV). AMERICAN JOURNAL OF CARDIOLOGY, 102(5), 546–551. -
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF
Hankey, G. J., Patel, M. R., Stevens, S. R., Becker, R. C., Breithardt, G., Carolei, A., … Hacke, W. (2012). Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. LANCET NEUROLOGY, 11(4), 315–322. -
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction - The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial
Mahaffey, K. W., Granger, C. B., Nicolau, J. C., Ruzyllo, W., Weaver, W. D., Theroux, P., … Armstrong, P. W. (2003). Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction - The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. CIRCULATION, 108(10), 1176–1183. -
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial
Lopes, R. D., Alexander, K. P., Marcucci, G., White, H. D., Spinler, S., Col, J., … Mahaffey, K. W. (2008). Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. EUROPEAN HEART JOURNAL, 29(15), 1827–1833. -
Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction
Mills, J. S., Mahaffey, K. W., Lokhnygina, Y., Nicolau, J. C., Ruzyllo, W., Adams, P. X., … Granger, C. B. (2012). Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction. CORONARY ARTERY DISEASE, 23(2), 118–125. -
Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT-AF Registry
Fosbol, E. L., Holmes, D. J. N., Piccini, J. P., Thomas, L., Reiffel, J. A., Mills, R. M., … Peterson, E. D. (2013). Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT-AF Registry. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2(4). -
The SYNERGY trial: Study design and rationale
Ferguson, J. J., Califf, R. M., Antman, E. M., Cohen, M., Grines, C. L., Kereiakes, D. J., … Rios-Nogales, L. (2002). The SYNERGY trial: Study design and rationale. AMERICAN HEART JOURNAL, 143(6), 952–960. -
Rivaroxaban, an oral direct factor Xa inhibitor
Piccini, J. P., Patel, M. R., Mahaffey, K. W., Fox, K. A. A., & Califf, R. M. (2008). Rivaroxaban, an oral direct factor Xa inhibitor. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 17(6), 925–937. -
Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF
Piccini, J. P., Fraulo, E. S., Ansell, J. E., Fonarow, G. C., Gersh, B. J., Go, A. S., … Peterson, E. D. (2011). Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF. AMERICAN HEART JOURNAL, 162(4), 606–U54. -
Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation Insights From ROCKET AF
van Diepen, S., Hellkamp, A. S., Patel, M. R., Becker, R. C., Breithardt, G., Hacke, W., … Mahaffey, K. W. (2013). Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation Insights From ROCKET AF. CIRCULATION-HEART FAILURE, 6(4), 740–747. -
Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention
Bagai, A., Schulte, P. J., Granger, C. B., Mahaffey, K. W., Christenson, R. H., Bell, G., … Roe, M. T. (2014). Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. AMERICAN HEART JOURNAL, 168(4), 503-? -
Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy
Chew, D. P., Huang, Z., Pieper, K. S., White, H., Mahaffey, K. W., Ferguson, J. J., … Aylward, P. G. (2008). Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy. AMERICAN HEART JOURNAL, 155(2), 239–244. -
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
Fox, K. A. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., … Califf, R. M. (2011). Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. EUROPEAN HEART JOURNAL, 32(19), 2387–2394. -
Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial
Wong, K. S. L., Hu, D. Y., Oomman, A., Tan, R.-S., Patel, M. R., Singer, D. E., … Hankey, G. J. (2014). Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial. STROKE, 45(6), 1739-? -
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
Mark, D. B., Harrington, R. A., Lincoff, A. M., Califf, R. M., Nelson, C. L., Tsiatis, A. A., … Topol, E. J. (2000). Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. CIRCULATION, 101(4), 366–371. -
Prediction of one-year survival in high-risk patients with acute coronary syndromes: Results from the SYNERGY trial
Mahaffey, K. W., Yang, Q., Pieper, K. S., Antman, E. M., White, H. D., Goodman, S. G., … Califf, R. M. (2008). Prediction of one-year survival in high-risk patients with acute coronary syndromes: Results from the SYNERGY trial. JOURNAL OF GENERAL INTERNAL MEDICINE, 23(3), 310–316. -
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., … Califf, R. M. (2011). Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. NEW ENGLAND JOURNAL OF MEDICINE, 365(10), 883–891. -
Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy A Subgroup Analysis of a Randomized Trial
Mahaffey, K. W., Wojdyla, D., Hankey, G. J., White, H. D., Nessel, C. C., Piccini, J. P., … Hacke, W. (2013). Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy A Subgroup Analysis of a Randomized Trial. ANNALS OF INTERNAL MEDICINE, 158(12), 861-? -
Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial
Miller, C. D., Banerjee, A., Mahaffey, K. W., Kontos, M. C., Fermann, G., Pollack, C. V., … Hoekstra, J. W. (2007). Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. EUROPEAN HEART JOURNAL, 28(9), 1079–1084. -
Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis
Mahaffey, K. W., Granger, C. B., Sloan, M. A., Thompson, T. D., Gore, J. M., Weaver, W. D., … Califf, R. M. (1998). Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis. CIRCULATION, 97(8), 757–764. -
The Impact of Postrandomization Crossover of Therapy in Acute Coronary Syndromes Care
Mahaffey, K. W., Pieper, K. S., Lokhnygina, Y., Califf, R. M., Antman, E. M., Kleiman, N. S., … Ferguson, J. J. (2011). The Impact of Postrandomization Crossover of Therapy in Acute Coronary Syndromes Care. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 4(2), 211–U119. -
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
Lopes, R. D., Lokhnygina, Y., Hasselblad, V., Newby, K. L., Yow, E., Granger, C. B., … Mahaffey, K. W. (2013). Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy. TRIALS, 14. -
Heart rate is associated with progression of atrial fibrillation, independent of rhythm
Holmqvist, F., Kim, S., Steinberg, B. A., Reiffel, J. A., Mahaffey, K. W., Gersh, B. J., … Piccini, J. P. (2015). Heart rate is associated with progression of atrial fibrillation, independent of rhythm. HEART, 101(11), 894–99. -
Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial)
Echols, M. R., Mahaffey, K. W., Banerjee, A., Pieper, K. S., Stebbins, A., Lansky, A., … Califf, R. M. (2007). Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial). AMERICAN JOURNAL OF CARDIOLOGY, 99(3), 315–321. -
Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: A systematic overview
Mahaffey, K. W., Van de Werf, F., Shernan, S. K., Granger, C. B., Verrier, E. D., Filloon, T. G., … Armstrong, P. W. (2006). Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: A systematic overview. AMERICAN HEART JOURNAL, 152(2), 291–296. -
Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
Mahaffey, K. W., Wampole, J. L., Stebbins, A., Berdan, L. G., Mcafee, D., Rorick, T. L., … Armstrong, P. W. (2011). Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. CONTEMPORARY CLINICAL TRIALS, 32(2), 178–187. -
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial
Leonardi, S., Stebbins, A., Lopes, R. D., Lokhnygina, Y., Todd, M., Bhatt, D. L., … Mahaffey, K. W. (2013). Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. CORONARY ARTERY DISEASE, 24(4), 321–327. -
Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial
Piccini, J. P., Hellkamp, A. S., Lokhnygina, Y., Patel, M. R., Harrell, F. E., Singer, D. E., … Califf, R. M. (2014). Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 3(2). -
Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Holmqvist, F., Guan, N., Zhu, Z., Kowey, P. R., Allen, L. A., Fonarow, G. C., … Gersh, B. J. (2015). Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). AMERICAN HEART JOURNAL, 169(5), 647–U93. -
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes
Rao, S. V., O'Grady, K., Pieper, K. S., Granger, C. B., Newby, L. K. I., Mahaffey, K. W., … Harrington, R. A. (2006). A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 47(4), 809–816. -
Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial
Piccini, J. P., Stevens, S. R., Lokhnygina, Y., Patel, M. R., Halperin, J. L., Singer, D. E., … Breithardt, G. (2013). Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 61(19), 1998–2006. -
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF
Jones, W. S., Hellkamp, A. S., Halperin, J., Piccini, J. P., Breithardt, G., Singer, D. E., … Patel, M. R. (2014). Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. EUROPEAN HEART JOURNAL, 35(4), 242–249. -
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: Results from 4 large clinical trials
Galla, J. M., Mahaffey, K. W., Sapp, S. K., Alexander, J. H., Roe, M. T., Ohman, E. M., … Topol, E. J. (2006). Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: Results from 4 large clinical trials. AMERICAN HEART JOURNAL, 151(1), 16–24. -
Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
Singer, D. E., Hellkamp, A. S., Piccini, J. P., Mahaffey, K. W., Lokhnygina, Y., Pan, G., … Fox, K. A. A. (2013). Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2(1). -
5-Year Results of a Randomized Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting Stents Final Results From the SPIRIT III Trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)
Gada, H., Kirtane, A. J., Newman, W., Sanz, M., Hermiller, J. B., Mahaffey, K. W., … Stone, G. W. (2013). 5-Year Results of a Randomized Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting Stents Final Results From the SPIRIT III Trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC-CARDIOVASCULAR INTERVENTIONS, 6(12), 1263–1266. -
Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort
Allen, L. A., Fonarow, G. C., Simon, D. J. N., Thomas, L. E., Marzec, L. N., Pokorney, S. D., … Piccini, J. P. (2015). Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 65(25), 2691–98. -
Publication or presentation of results from multicenter clinical trials: Evidence from an academic medical center
Turer, A. T., Mahaffey, K. W., Compton, K. L., Califf, R. M., & Schulman, K. A. (2007). Publication or presentation of results from multicenter clinical trials: Evidence from an academic medical center. AMERICAN HEART JOURNAL, 153(4), 674–80. -
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes
Califf, R. M., Petersen, J. L., Hasselblad, V., Mahaffey, K. W., & Ferguson, J. J. (2005). A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. AMERICAN HEART JOURNAL, 149(4), S91–S99. -
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin
Thomas, M. P., Mahaffey, K. W., Chiswell, K., Cohen, M., Kontos, M. C., Antman, E. M., … Becker, R. C. (2012). Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 34(1), 114–119. -
ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction - Insights from the Assessment of PEXelizumab in Acute Myocardial Infarction (APEX-AMI) trial
Buller, C. E., Fu, Y., Mahaffey, K. W., Todaro, T. G., Adams, P., Westerhout, C. M., … Armstrong, P. W. (2008). ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction - Insights from the Assessment of PEXelizumab in Acute Myocardial Infarction (APEX-AMI) trial. CIRCULATION, 118(13), 1335–1346. -
The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: An AMISTAD substudy
Barbagelata, A., Di Carli, M. F., Sgarbossa, E. B., Califf, R. M., Clemmensen, P., Criger, D. A., … Mahaffey, K. W. (1999). The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: An AMISTAD substudy. Presented at the 24th Annual ISCE Conference on Research and Technology Transfer in Computerized Electrocardiology, NARA,JAPAN: CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS. -
Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization.
Bagai, A., Huang, Z., Lokhnygina, Y., Harrington, R. A., Armstrong, P. W., Strony, J., … Mahaffey, K. W. (2015). Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. Circulation. Cardiovascular Interventions, 8(6). -
Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes
Mahaffey, K. W., Hager, R., Wojdyla, D., White, H. D., Armstrong, P. W., Alexander, J. H., … Wallentin, L. (2015). Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 4(6). -
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Cornel, J. H., Tricoci, P., Lokhnygina, Y., Moliterno, D. J., Wallentin, L., Armstrong, P. W., … Harrington, R. A. (2015). Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). American Journal of Cardiology, 115(10), 1325–32. -
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years.
Kragholm, K., Halim, S. A., Yang, Q., Schulte, P. J., Hochman, J. S., Melloni, C., … Newby, L. K. (2015). Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. Circulation. Cardiovascular Quality and Outcomes, 8(4), 357–67. -
Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
Freeman, J. V., Simon, D. J. N., Go, A. S., Spertus, J., Fonarow, G. C., Gersh, B. J., … Piccini, J. P. (2015). Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation. Cardiovascular Quality and Outcomes, 8(4), 393–402. -
Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: Results from the PURSUIT trial
Al-Khatib, S. M., Pieper, K. S., Lee, K. L., Mahaffey, K. W., Hochman, J. S., Pepine, C. J., … Harrington, R. A. (2001). Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: Results from the PURSUIT trial. AMERICAN JOURNAL OF CARDIOLOGY, 88(1), 76–79. -
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents
Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., … Wesley, D. J. (2010). ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. CIRCULATION, 122(24), 2619–33. -
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients Insights From Clinical Trials Over 17 Years
Kragholm, K., Halim, S. A., Yang, Q., Schulte, P. J., Hochman, J. S., Melloni, C., … Newby, L. K. (2015). Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients Insights From Clinical Trials Over 17 Years. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 8(4), 357–67. -
Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Freeman, J. V., Simon, D. J. N., Go, A. S., Spertus, J., Fonarow, G. C., Gersh, B. J., … Piccini, J. P. (2015). Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 8(4), 393–402. -
ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.
Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., … Tomaselli, G. F. (2010). ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation, 122(24), 2619–2633. -
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents
Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., … Tomaselli, G. F. (2010). ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 56(24), 2051–2066. -
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from SYNERGY
Spinler, S. A., Mahaffey, K. W., Gallup, D., Levine, G. N., Ferguson, J. J., Rao, S. V., … Califf, R. M. (2010). Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from SYNERGY. INTERNATIONAL JOURNAL OF CARDIOLOGY, 144(1), 36–41. -
Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion
Roe, M. T., Ohman, E. M., Maas, A. C. P., Christenson, R. H., Mahaffey, K. W., Granger, C. B., … Krucoff, M. W. (2001). Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 37(1), 9–18. -
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation
Alexander, J. H., Sparapani, R. A., Mahaffey, K. W., Deckers, J. W., Newby, L. K., Ohman, E. M., … Harrington, R. A. (2000). Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 283(3), 347–53. -
Myonecrosis after revascularization procedures
Califf, R. M., Abdelmeguid, A. E., Kuntz, R. E., Popma, J. J., Davidson, C. J., Cohen, E. A., … Ohman, E. M. (1998). Myonecrosis after revascularization procedures. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 31(2), 241–51. -
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?
HERSI, A., Fu, Y., Wong, B., Mahaffey, K. W., Harrington, R. A., Califf, R. M., … Armstrong, P. W. (2003). Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission? EUROPEAN HEART JOURNAL, 24(6), 524–33. -
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
Lopes, R. D., Pieper, K. S., Horton, J. R., Al-Khatib, S. M., Newby, L. K., Mehta, R. H., … Granger, C. B. (2008). Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. HEART, 94(7), 867–73. -
The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations.
Roe, M. T., Mahaffey, K. W., Ezekowitz, J. A., Alexander, J. H., Goodman, S. G., Hernandez, A., … Armstrong, P. W. (2015). The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. American Heart Journal, 169(6), 743–50. -
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials
Angiolillo, D. J., Bhatt, D. L., Steg, P. G., Stone, G. W., White, H. D., Gibson, C. M., … Harrington, R. A. (2015). Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 40(3), 317–22. -
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Weiss, R., … Neal, B. (2015). Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, 6(3), 289–302. -
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes - Results from PURSUIT
Akkerhuis, K. M., Deckers, J. W., Boersma, E., Harrington, R. A., Stepinska, J., Mahaffey, K. W., … Simoons, M. L. (2000). Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes - Results from PURSUIT. EUROPEAN HEART JOURNAL, 21(5), 371–381. -
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal, S., Bloomgarden, Z., Halperin, J. L., Hellkamp, A. S., Lokhnygina, Y., Patel, M. R., … Fox, K. A. A. (2015). Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). American Heart Journal, 170(4), 675–82 e8. -
Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF)
Steinberg, B. A., Kim, S., Thomas, L., Fonarow, G. C., Gersh, B. J., Holmqvist, F., … Piccini, J. P. (2015). Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). JOURNAL OF THE AMERICAN HEART ASSOCIATION, 4(9). -
Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study)
Yong, C., Azarbal, F., Abnousi, F., Heidenreich, P. A., Schmitt, S., Fan, J., … Turakhia, M. P. (2016). Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study). AMERICAN JOURNAL OF CARDIOLOGY, 117(1), 61–68. -
Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunction.
Kuznetsova, T., Haddad, F., Knez, J., Rosenberg-Hasson, Y., Sung, J., Cauwenberghs, N., … Staessen, J. A. (2015). Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunction. Journal of the American Society of Hypertension , 9(12), 975–84 e3. -
Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Mathieu, C., … Neal, B. (2016). Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. DIABETES OBESITY & METABOLISM, 18(1), 82–91. -
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
O'Donoghue, M. L., Bhatt, D. L., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., … Harrington, R. A. (2016). Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. CIRCULATION, 133(3), 248–55. -
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction
Pokorney, S. D., Radder, C., Schulte, P. J., Al-Khatib, S. M., Tricocci, P., Van de Werf, F., … Piccini, J. P. (2016). High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. AMERICAN HEART JOURNAL, 171(1), 25–32. -
Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunction
Kuznetsova, T., Haddad, F., Knez, J., Rosenberg-Hasson, Y., Sung, J., Cauwenberghs, N., … Staessen, J. A. (2015). Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunction. JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 9(12), 975–84. -
Influence of Clinical Trial Participation on Subsequent Antithrombin Use
Shah, B. R., Peterson, E. D., Chen, A. Y., Mahaffey, K. W., DeLong, E. R., Ohman, E. M., … Roe, M. T. (2010). Influence of Clinical Trial Participation on Subsequent Antithrombin Use. CLINICAL CARDIOLOGY, 33(3), E49–E55. -
Promise of Factor Xa Inhibition in Atrial Fibrillation
Al-Khatib, S. M., Alexander, J. H., Lopes, R. D., Mahaffey, K. W., Patel, M. R., & Granger, C. B. (2012). Promise of Factor Xa Inhibition in Atrial Fibrillation. CURRENT CARDIOLOGY REPORTS, 14(1). -
Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
Tcheng, J. E., Lincoff, A. M., Sigmon, K. N., Lee, K. L., Kitt, M. M., Califf, R. M., … Swift, R. (1997). Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. LANCET, 349(9063), 1422–28. -
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin ROCKET AF Trial
Sherwood, M. W., Nessel, C. C., Hellkamp, A. S., Mahaffey, K. W., Piccini, J. P., Suh, E.-Y., … Patel, M. R. (2015). Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin ROCKET AF Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 66(21), 2271–81. -
Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis
Parfrey, P. S., Block, G. A., Correa-Rotter, R., Drueeke, T. B., Floege, J., Herzog, C. A., … Chertow, G. M. (2016). Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 11(3), 539–546. -
The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial
Chang, T. I., AbdAlla, S., London, G. M., Block, G. A., Correa-Rotter, R., Drueeke, T. B., … Chertow, G. M. (2016). The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. JOURNAL OF HUMAN HYPERTENSION, 30(3), 204–9. -
Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry
Golwala, H., Jackson, L. R., Simon, D. J. N., Piccini, J. P., Gersh, B., Go, A. S., … Thomas, K. L. (2016). Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. AMERICAN HEART JOURNAL, 174, 29–36. -
Pooled analysis of adverse event collection from 4 acute coronary syndrome trials
Zimerman, A., Lopes, R. D., Stebbins, A. L., Guimaraes, P. O., Haque, G., Melloni, C., … Alexander, K. P. (2016). Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. AMERICAN HEART JOURNAL, 174, 60–67. -
Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery.
van Diepen, S., Tricoci, P., Podder, M., Westerhout, C. M., Aylward, P. E., Held, C., … Armstrong, P. W. (2015). Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. Journal of the American Heart Association, 4(12). -
Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry
Jackson, L. R., Kim, S. H., Piccini, J. P., Gersh, B. J., Naccarelli, G. V., Reiffel, J. A., … Kowey, P. R. (2016). Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry. CLINICAL CARDIOLOGY, 39(2), 119–25. -
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
O'Brien, E. C., Simon, D. J. N., Thomas, L. E., Hylek, E. M., Gersh, B. J., Ansell, J. E., … Peterson, E. D. (2015). The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. European Heart Journal, 36(46), 3258–64. -
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
Gutierrez, J. A., Harrington, R. A., Blankenship, J. C., Stone, G. W., Steg, P. G., Gibson, C. M., … Bhatt, D. L. (2016). The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. EUROPEAN HEART JOURNAL, 37(14), 1122–30. -
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: The SYNERGY trial
Mahaffey, K. W., & Ferguson, J. J. (2005). Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: The SYNERGY trial. AMERICAN HEART JOURNAL, 149(4), S81–S90. -
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: Experience from the GUSTO-I Trial
Mahaffey, K. W., Granger, C. B., Sloan, M. A., Green, C. L., Gore, J. M., Weaver, W. D., … Califf, R. M. (1999). Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: Experience from the GUSTO-I Trial. AMERICAN HEART JOURNAL, 138(3), 493–499. -
Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial
Zhang, M., Tsiatis, A. A., Davidian, M., Pieper, K. S., & Mahaffey, K. W. (2011). Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial. BIOSTATISTICS, 12(2), 258–269. -
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study
Bagai, A., Armstrong, P. W., Stebbins, A., Mahaffey, K. W., Hochman, J. S., Weaver, W. D., … Lopes, R. D. (2013). Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study. AMERICAN HEART JOURNAL, 166(5), 913–919. -
Prognostic usefulness of White Blood Cell count and temperature in acute myocardial infarction (from the CARDINAL Trial)
Patel, M. R., Mahaffey, K. W., Armstrong, P. W., Weaver, W. D., Tasissa, G., Hochman, J. S., … Granger, C. B. (2005). Prognostic usefulness of White Blood Cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). AMERICAN JOURNAL OF CARDIOLOGY, 95(5), 614–618. -
Effects of stroke on medical resource use and costs in acute myocardial infarction
Tung, C. Y., Granger, C. B., Sloan, M. A., Topol, E. J., KNIGHT, J. D., Weaver, W. D., … Mark, D. B. (1999). Effects of stroke on medical resource use and costs in acute myocardial infarction. CIRCULATION, 99(3), 370–376. -
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome
Becker, R. C., Mahaffey, K. W., Yang, H., Marian, A. J., Furman, M. I., Lincoff, A. M., … Kleiman, N. S. (2011). Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 31(2), 146–153. -
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy
van Diepen, S., Newby, L. K., Lopes, R. D., Stebbins, A., Hasselblad, V., James, S., … Theroux, P. (2013). Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy. INTERNATIONAL JOURNAL OF CARDIOLOGY, 168(3), 2127–2133. -
Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes - A review and guide to patient selection
Atwater, B. D., Roe, M. T., & Mahaffey, K. W. (2005). Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes - A review and guide to patient selection. DRUGS, 65(3), 313–324. -
Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage
Sloan, M. A., Sila, C. A., Mahaffey, K. W., Granger, C. B., Longstreth, W. T., Koudstaal, P., … Califf, R. M. (1998). Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. CIRCULATION, 98(14), 1376–1382. -
Association of Myocardial Enzyme Elevation and Survival Following Coronary Artery Bypass Graft Surgery
Domanski, M. J., Mahaffey, K., Hasselblad, V., Brener, S. J., Smith, P. K., Hillis, G., … Farkouh, M. E. (2011). Association of Myocardial Enzyme Elevation and Survival Following Coronary Artery Bypass Graft Surgery. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 305(6), 585–591. -
The Systemic Inflammatory Response Syndrome in Patients With ST-Segment Elevation Myocardial Infarction
van Diepen, S., Vavalle, J. P., Newby, L. K., Clare, R., Pieper, K. S., Ezekowitz, J. A., … Granger, C. B. (2013). The Systemic Inflammatory Response Syndrome in Patients With ST-Segment Elevation Myocardial Infarction. CRITICAL CARE MEDICINE, 41(9), 2080–2087. -
Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome
Vora, A. N., Chenier, M., Schulte, P. J., Goodman, S., Peterson, E. D., Pieper, K., … Wang, T. Y. (2014). Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. AMERICAN HEART JOURNAL, 168(2), 189-? -
Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials
Russell, S. D., Blackwell, K. L., Lawrence, J., Pippen, J. E., Roe, M. T., Wood, F., … Mahaffey, K. W. (2010). Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials. JOURNAL OF CLINICAL ONCOLOGY, 28(21), 3416–3421. -
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct
Lopes, R. D., Dickerson, S., Hafley, G., Burns, S., Tourt-Uhlig, S., White, J., … Mahaffey, K. W. (2013). Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct. AMERICAN HEART JOURNAL, 166(2), 208-? -
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Patients with Non-valvular Atrial Fibrillation: Results from ROCKET AF
Girgis, I. G., Patel, M. R., Peters, G. R., Moore, K. T., Mahaffey, K. W., Nessel, C. C., … Becker, R. C. (2014). Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Patients with Non-valvular Atrial Fibrillation: Results from ROCKET AF. JOURNAL OF CLINICAL PHARMACOLOGY, 54(8), 917–927. -
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy - Primary results of the SYNERGY randomized trial
Ferguson, J. J., Califf, R. M., Antman, E. M., Cohen, M., Grines, C. L., Goodman, S., … White, H. (2004). Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy - Primary results of the SYNERGY randomized trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 292(1), 45–54. -
Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial
Gebel, J. M., Sila, C. A., Sloan, M. A., Granger, C. B., Weisenberger, J. P., Green, C. L., … Mahaffey, K. W. (1998). Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial. STROKE, 29(9), 1799–1801. -
Mechanical Complications After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction (from APEX-AMI)
French, J. K., Hellkamp, A. S., Armstrong, P. W., Cohen, E., Kleiman, N. S., O'Connor, C. M., … Mahaffey, K. W. (2010). Mechanical Complications After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction (from APEX-AMI). AMERICAN JOURNAL OF CARDIOLOGY, 105(1), 59–63. -
Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: Validity, pitfalls, and future approaches
Subherwal, S., Ohman, E. M., Mahaffey, K. W., Rao, S. V., Alexander, J. H., Wang, T. Y., … Roe, M. T. (2013). Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: Validity, pitfalls, and future approaches. AMERICAN HEART JOURNAL, 165(5), 644-? -
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Piccini, J. P., Hellkamp, A. S., Washam, J. B., Becker, R. C., Breithardt, G., Berkowitz, S. D., … Patel, M. R. (2016). Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation, 133(4), 352–60. -
Thrombolysis-related intracranial hemorrhage - A radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation
Gebel, J. M., Sila, C. A., Sloan, M. A., Granger, C. B., Mahaffey, K. W., Weisenberger, J., … Topol, E. J. (1998). Thrombolysis-related intracranial hemorrhage - A radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. STROKE, 29(3), 563–569. -
Enoxaparin 0.3 mg/kg IV Supplement for Patients Transitioning to PCI after Subcutaneous Enoxaparin Therapy for NSTE ACS: A Subgroup Analysis from the SYNERGY Trial
Cohen, M., Levine, G. N., Pieper, K. S., Lan, L., Antman, E. M., Aylward, P. E., … Mahaffey, K. W. (2010). Enoxaparin 0.3 mg/kg IV Supplement for Patients Transitioning to PCI after Subcutaneous Enoxaparin Therapy for NSTE ACS: A Subgroup Analysis from the SYNERGY Trial. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 75(6), 928–935. -
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention
Westerhout, C. M., Pieper, K. S., James, S. K., Mahaffey, K. W., Van de Werf, F., Califf, R. M., … Armstrong, P. W. (2013). Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. AMERICAN HEART JOURNAL, 165(3), 354-? -
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-I trial)
Kandzari, D. E., Granger, C. B., Simoons, M. L., White, H. D., Simes, J., Mahaffey, K. W., … Topol, E. J. (2004). Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-I trial). AMERICAN JOURNAL OF CARDIOLOGY, 93(4), 458–461. -
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: Enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes
Cohen, M., Mahaffey, K. W., Pieper, K., Pollack, C. V., Antman, E. M., Hoekstra, J., … Ferguson, J. J. (2006). A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: Enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 48(7), 1346–1354. -
Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes
Yan, R. T., Yan, A. T., Mahaffey, K. W., White, H. D., Pieper, K., Sun, J.-L., … Goodman, S. G. (2010). Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. EUROPEAN HEART JOURNAL, 31(8), 958–966. -
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes
Alexander, J. H., Harrington, R. A., Bhapkar, M., Mahaffey, K. W., Lincoff, A. M., Ohman, E. M., … Wagner, G. S. (2003). Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. AMERICAN JOURNAL OF MEDICINE, 115(8), 613–619. -
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study
Goyal, A., Mahaffey, K. W., Garg, J., Nicolau, J. C., Hochman, J. S., Weaver, W. D., … Granger, C. B. (2006). Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. EUROPEAN HEART JOURNAL, 27(11), 1289–1297. -
Resolution of ST-segment depression: a new prognostic marker in ST-segment elevation myocardial infarction
Tjandrawidjaja, M. C., Fu, Y., Westerhout, C. M., White, H. D., Todaro, T. G., Van de Werf, F., … Armstrong, P. W. (2010). Resolution of ST-segment depression: a new prognostic marker in ST-segment elevation myocardial infarction. EUROPEAN HEART JOURNAL, 31(5), 573–581. -
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack
James, S. K., Storey, R. F., Khurmi, N. S., Husted, S., Keltai, M., Mahaffey, K. W., … Becker, R. C. (2012). Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. CIRCULATION, 125(23), 2914-? -
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction - The COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial
Granger, C. B., Mahaffey, K. W., Weaver, W. D., Theroux, P., Hochman, J. S., Filloon, T. G., … Armstrong, P. W. (2003). Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction - The COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. CIRCULATION, 108(10), 1184–1190. -
Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease
Turer, A. T., Mahaffey, K. W., Honeycutt, E., Tuttle, R. H., Shaw, L. K., Sketch, M. H., … Alexander, J. H. (2009). Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 137(6), 1468–1474. -
Search for a diagnostic/prognostic biomarker for the brain cancer glioblastoma multiforme by 2D-DIGE-MS technique
Banerjee, H. nath, Mahaffey, K., Riddick, E., Banerjee, A., Bhowmik, N., & Patra, M. (2012). Search for a diagnostic/prognostic biomarker for the brain cancer glioblastoma multiforme by 2D-DIGE-MS technique. MOLECULAR AND CELLULAR BIOCHEMISTRY, 367(1-2), 59–63. -
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction
Aviles, R. J., Askari, A. T., Lindahl, B., Wallentin, L., Jia, G., Ohman, E. M., … Berger, P. (2002). Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. NEW ENGLAND JOURNAL OF MEDICINE, 346(26), 2047–2052. -
Statin use and sex-specific stroke outcomes in patients with vascular disease
Bushnell, C. D., Griffin, J., Newby, L. K., Goldstein, L. B., Mahaffey, K. W., Graffagnino, C. A., … Easton, J. D. (2006). Statin use and sex-specific stroke outcomes in patients with vascular disease. STROKE, 37(6), 1427–1431. -
Baseline Q-Wave Surpasses Time From Symptom Onset as a Prognostic Marker in ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention
Armstrong, P. W., Fu, Y., Westerhout, C. M., Hudson, M. P., Mahaffey, K. W., White, H. D., … Granger, C. B. (2009). Baseline Q-Wave Surpasses Time From Symptom Onset as a Prognostic Marker in ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 53(17), 1503–1509. -
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial
van Diepen, S., Roe, M. T., Lopes, R. D., Stebbins, A., James, S., Newby, L. K., … Granger, C. B. (2012). Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 34(1), 106–113. -
Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis
Birnbaum, Y., Mahaffey, K. W., Criger, D. A., Gates, K. B., Barbash, G. I., Barbagelata, A., … Wagner, G. S. (2002). Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis. CARDIOLOGY, 97(3), 166–174. -
N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction
Ezekowitz, J. A., Theroux, P., Chang, W. C., Mahaffey, K. W., Granger, C. B., Weaver, W. D., … Armstrong, P. W. (2006). N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. CANADIAN JOURNAL OF CARDIOLOGY, 22(5), 393–397. -
Initial risk stratification and presenting characteristics of patients with evolving myocardial infarctions
Miller, C. D., Fermann, G. J., Lindsell, C. J., Mahaffey, K. W., Peacock, W. F., Pollack, C. V., … Hoekstra, J. W. (2008). Initial risk stratification and presenting characteristics of patients with evolving myocardial infarctions. EMERGENCY MEDICINE JOURNAL, 25(8), 492–497. -
Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: Results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial
Berger, P. B., Mahaffey, K. W., Meier, S. J., Buller, C. E., Batchelor, W., Fry, E. T. A., & Zidar, J. P. (2002). Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: Results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. AMERICAN HEART JOURNAL, 143(5), 841–846. -
Comparing classifications of death in the Mode Selection Trial: Agreement and disagreement among site investigators and a clinical events committee
Petersen, J. L., Haque, G., Hellkarnp, A. S., Flaker, G. C., Estes, N. A. M., Marchlinski, F. E., … Mahaffey, K. W. (2006). Comparing classifications of death in the Mode Selection Trial: Agreement and disagreement among site investigators and a clinical events committee. CONTEMPORARY CLINICAL TRIALS, 27(3), 260–268. -
Management of acute coronary syndromes in patients with renal dysfunction
Melloni, C., & Mahaffey, K. W. (2008). Management of acute coronary syndromes in patients with renal dysfunction. CURRENT OPINION IN CARDIOLOGY, 23(4), 320–326. -
Determinants of plasma vitamin D levels in patients with acute coronary syndromes
Rodriguez, G., Starr, A. Z., Czernuszewicz, G. Z., Manhas, A., Alhariri, A., Willerson, J. T., … Kleiman, N. S. (2011). Determinants of plasma vitamin D levels in patients with acute coronary syndromes. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 41(12), 1299–1309. -
A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: The ATLAST trial
Batchelor, W. B., Mahaffey, K. W., Berger, P. B., DEUTSCH, E., Meier, S., Hasselblad, V., … Zidar, J. P. (2001). A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: The ATLAST trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 38(6), 1608–1613. -
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry
Szummer, K. E., Solomon, S. D., Velazquez, E. J., Kilaru, R., McMurray, J., Rouleau, J. L., … White, H. D. (2005). Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. EUROPEAN HEART JOURNAL, 26(20), 2114–2119. -
Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict
Chew, D. P., Mahaffey, K. W., White, H. D., Huang, Z., Hockstra, J. W., Ferguson, J. J., … Aylward, P. E. (2008). Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict. AMERICAN HEART JOURNAL, 155(5), 841–847. -
Mode of Death and Hospitalization from the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial and Comparison of Clinical Events Committee Adjudicated Versus Investigator Reported Outcomes
O'Connor, C. M., Fiuzat, M., Lindenfeld, J., Miller, A., Lombardi, C., Carson, P., … Mahaffey, K. (2011). Mode of Death and Hospitalization from the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial and Comparison of Clinical Events Committee Adjudicated Versus Investigator Reported Outcomes. AMERICAN JOURNAL OF CARDIOLOGY, 108(10), 1449–1457. -
Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction
Armstrong, P. W., Mahaffey, K. W., Chang, W. C., Weaver, W. D., Hochman, J. S., Theroux, P., … Granger, C. B. (2006). Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. AMERICAN HEART JOURNAL, 151(4), 787–790. -
Electrocardiographic infarct size assessment after thrombolysis: Insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial
Barbagelata, A., Di Carli, M. F., Califf, R. M., Garg, J., Birnbaum, Y., Grinfeld, L., … Mahaffey, K. W. (2005). Electrocardiographic infarct size assessment after thrombolysis: Insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial. AMERICAN HEART JOURNAL, 150(4), 659–665. -
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
Murphy, S. A., Gibson, C. M., Morrow, D. A., de Werf, F. V., Menown, I. B., Goodman, S. G., … Braunwald, E. (2007). Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. EUROPEAN HEART JOURNAL, 28(17), 2077–2086. -
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: Observations from "Assessment of Pexelizumab in Acute Myocardial Infarction"
French, J. K., Armstrong, P. W., Cohen, E., Kleiman, N. S., O'Connor, C. M., Hellkamp, A. S., … Mahaffey, K. W. (2011). Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: Observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". AMERICAN HEART JOURNAL, 162(1), 89–97. -
Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury
Kuster, D. W. D., Cardenas-Ospina, A., Miller, L., Liebetrau, C., Troidl, C., Nef, H. M., … Sadayappan, S. (2014). Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 306(4), H547–H556. -
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction
Chang, W. C., Kaul, P., Fu, Y. L., Westerhout, C. M., Granger, C. B., Mahaffey, K. W., … Armstrong, P. W. (2006). Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction. EUROPEAN HEART JOURNAL, 27(4), 419–426. -
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial
Theroux, P., Armstrong, P. W., Mahaffey, K. W., Hochman, J. S., Malloy, K. J., Rollins, S., … Granger, C. B. (2005). Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. EUROPEAN HEART JOURNAL, 26(19), 1964–1970. -
Overview of randomized trials of intravenous heparin in patients with acute acute myocardial infarction treated with thrombolytic therapy
Mahaffey, K. W., Granger, C. B., Collins, R., OCONNOR, C. M., Ohman, E. M., Bleich, S. D., … Califf, R. M. (1996). Overview of randomized trials of intravenous heparin in patients with acute acute myocardial infarction treated with thrombolytic therapy. AMERICAN JOURNAL OF CARDIOLOGY, 77(8), 551–556. -
Prognosis of patients taking selective serotonin reuptake inhihitors before coronary artery bypass grafting
Xiong, G. L., Jiang, W., Clare, R., Shaw, L. K., Smith, P. K., Mahaffey, K. W., … Newby, L. K. (2006). Prognosis of patients taking selective serotonin reuptake inhihitors before coronary artery bypass grafting. AMERICAN JOURNAL OF CARDIOLOGY, 98(1), 42–47. -
Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes
Galla, J. M., & Mahaffey, K. W. (2005). Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes. EXPERT OPINION ON PHARMACOTHERAPY, 6(7), 1241–1251. -
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction - Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) Trial
Mahaffey, K. W., Puma, J. A., Barbagelata, N. A., DiCarli, M. F., Leesar, M. A., Browne, K. F., … Granger, C. B. (1999). Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction - Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 34(6), 1711–1720. -
Mortality Implications of Primary Percutaneous Coronary Intervention Treatment Delays: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction Trial
Hudson, M. P., Armstrong, P. W., O'Neil, W. W., Stebbins, A. L., Weaver, W. D., Widimsky, P., … Granger, C. B. (2011). Mortality Implications of Primary Percutaneous Coronary Intervention Treatment Delays: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 4(2), 183–192. -
Lost to Follow-up and Withdrawal of Consent in Contemporary Global Cardiovascular Randomized Clinical Trials.
Rodriguez, F., Harrison, R. W., Wojdyla, D., & Mahaffey, K. W. (2015). Lost to Follow-up and Withdrawal of Consent in Contemporary Global Cardiovascular Randomized Clinical Trials. Critical Pathways in Cardiology, 14(4), 150–53. -
Pooled analysis of adverse event collection from 4 acute coronary syndrome trials.
Zimerman, A., Lopes, R. D., Stebbins, A. L., Guimarães, P. O., Haque, G., Melloni, C., … Alexander, K. P. (2016). Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. American Heart Journal, 174, 60–67. -
Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry.
Golwala, H., Jackson, L. R., Simon, D. J. N., Piccini, J. P., Gersh, B., Go, A. S., … Thomas, K. L. (2016). Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. American Heart Journal, 174, 29–36. -
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
Pokorney, S. D., Piccini, J. P., Stevens, S. R., Patel, M. R., Pieper, K. S., Halperin, J. L., … Califf, R. M. (2016). Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Journal of the American Heart Association, 5(3). -
ESC Guidelines on the management of acute myocardial infarction with persistent ST-segment elevation
Steg, G., James, S. K., Atar, D., Badano, L. P., Lundquist, C. B., Borger, M. A., … Zahger, D. (2012). ESC Guidelines on the management of acute myocardial infarction with persistent ST-segment elevation. KARDIOLOGIA POLSKA, 70, S255–S318. -
DELTA-AMINOLEVULINIC-ACID DEHYDRATASE - SENSITIVE INDICATOR OF LEAD-EXPOSURE IN JAPANESE QUAIL
Stone, C. L., FOX, M. R. S., Jones, A. L., & Mahaffey, K. R. (1977). DELTA-AMINOLEVULINIC-ACID DEHYDRATASE - SENSITIVE INDICATOR OF LEAD-EXPOSURE IN JAPANESE QUAIL. POULTRY SCIENCE, 56(1), 174–181. -
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards ( Writing Committee to Develop Cardiovascular Endpoints Data Standards)
Hicks, K. A., Tcheng, J. E., Bozkurt, B., Chaitman, B. R., Cutlip, D. E., Farb, A., … Wang, T. Y. (2015). 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards ( Writing Committee to Develop Cardiovascular Endpoints Data Standards). CIRCULATION, 132(4), 302–361. -
A comparison of reteplase with alteplase for acute myocardial infarction
Topol, E., Califf, R., Ohman, E., Wilcox, R., Grinfeld, L., Aylward, P., … Sloan, M. (1997). A comparison of reteplase with alteplase for acute myocardial infarction. NEW ENGLAND JOURNAL OF MEDICINE, 337(16), 1118–1123. -
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
Topol, E. J., Califf, R. M., Lincoff, A. M., Tcheng, J. E., Cabot, C. F., Weisman, H. F., … Stoner, G. L. (1997). Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. NEW ENGLAND JOURNAL OF MEDICINE, 336(24), 1689–1696. -
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)
Hicks, K. A., Tcheng, J. E., Bozkurt, B., Chaitman, B. R., Cutlip, D. E., Farb, A., … Wang, T. Y. (2015). 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 66(4), 403–469. -
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?
HERSI, A., Fu, Y., Wong, B., Mahaffey, K. W., Harrington, R. A., Califf, R. M., … Armstrong, P. W. (2003). Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission? European Heart Journal, 24(6), 522–531. -
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).
Hicks, K. A., Tcheng, J. E., Bozkurt, B., Chaitman, B. R., Cutlip, D. E., Farb, A., … Targum, S. L. (2015). 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). Journal of the American College of Cardiology, 66(4), 403–469. -
RAPID BIOASSAY SYSTEM FOR LEAD USING YOUNG JAPANESE QUAIL
Stone, C. L., Mahaffey, K. R., & FOX, M. R. S. (1979). RAPID BIOASSAY SYSTEM FOR LEAD USING YOUNG JAPANESE QUAIL. JOURNAL OF ENVIRONMENTAL PATHOLOGY AND TOXICOLOGY, 2(3), 767–779. -
Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromes.
Kandzari, D. E., & Mahaffey, K. W. (2002). Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromes. Journal of Interventional Cardiology, 15(2), 121–129. -
Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil.
Lopes, R. D., Becker, R. C., Newby, L. K., Peterson, E. D., Hylek, E. M., Giugliano, R., … Garcia, D. A. (2013). Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil. Journal of Thrombosis and Thrombolysis, 36(1), 115–130. -
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.
Mahaffey, K. W., Roe, M. T., Dyke, C. K., Newby, L. K., Kleiman, N. S., Connolly, P., … Harrington, R. A. (2002). Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. American Heart Journal, 143(2), 242–248. -
Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial.
Al-Khatib, S. M., Pieper, K. S., Lee, K. L., Mahaffey, K. W., Hochman, J. S., Pepine, C. J., … Harrington, R. A. (2001). Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. American Journal of Cardiology, 88(1), A7-? -
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
Steg, P. G., James, S. K., Atar, D., Badano, L. P., Blomstrom-Lundqvist, C., Borger, M. A., … Zahger, D. (2012). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. EUROPEAN HEART JOURNAL, 33(20), 2569–2619. -
INFLUENCE OF ETHANOL INGESTION ON LEAD TOXICITY IN RATS FED ISOCALORIC DIETS
Mahaffey, K. R., Goyer, R. A., & Wilson, M. H. (1974). INFLUENCE OF ETHANOL INGESTION ON LEAD TOXICITY IN RATS FED ISOCALORIC DIETS. ARCHIVES OF ENVIRONMENTAL HEALTH, 28(4), 217–222. -
Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
Campbell, K. R., Mahaffey, K. W., Lewis, B. E., Weitz, J. I., Berkowitz, S. D., Ohman, E. M., & Califf, R. M. (2000). Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. Journal of Invasive Cardiology, 12, 14F–9. -
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
Frederich, R., Alexander, J. H., Fiedorek, F. T., Donovan, M., Berglind, N., Harris, S., … Mahaffey, K. W. (2010). A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes. POSTGRADUATE MEDICINE, 122(3), 16–27. -
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
Goodman, S. G., Wojdyla, D. M., Piccini, J. P., White, H. D., Paolini, J. F., Nessel, C. C., … Califf, R. M. (2014). Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). Journal of the American College of Cardiology, 63(9), 891–900. -
Promise of factor Xa inhibition in atrial fibrillation.
Al-Khatib, S. M., Alexander, J. H., Lopes, R. D., Mahaffey, K. W., Patel, M. R., & Granger, C. B. (2012). Promise of factor Xa inhibition in atrial fibrillation. Current Cardiology Reports, 14(1), 70–78. -
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).
Hicks, K. A., Tcheng, J. E., Bozkurt, B., Chaitman, B. R., Cutlip, D. E., Farb, A., … Targum, S. L. (2015). 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). Journal of Nuclear Cardiology , 22(5), 1041–1144. -
Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies
Waters, R. E., Mahaffey, K. W., Granger, C. B., & Roe, M. T. (2003). Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. AMERICAN HEART JOURNAL, 146(6), 958–968. -
Promises of PAR-1 inhibition in acute coronary syndrome.
Leonardi, S., Tricoci, P., & Mahaffey, K. W. (2012). Promises of PAR-1 inhibition in acute coronary syndrome. Current Cardiology Reports, 14(1), 32–39. -
Baseline glucose and left ventricular remodeling after acute myocardial infarction
Nicolau, J. C., Maia, L. N., Vitola, J. V., Mahaffey, K. W., Machado, M. N., & Ramires, J. A. F. (2007). Baseline glucose and left ventricular remodeling after acute myocardial infarction. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 21(5), 294–299. -
Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction
Lofthus, D. M., Stevens, S. R., Armstrong, P. W., Granger, C. B., & Mahaffey, K. W. (2012). Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction. CORONARY ARTERY DISEASE, 23(1), 22–30. -
Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: Review of ocular hemorrhage incidence and location in the GUSTO-I trial
Mahaffey, K. W., Granger, C. B., Toth, C. A., White, H. D., Stebbins, A. L., Barbash, G. I., … Califf, R. M. (1997). Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: Review of ocular hemorrhage incidence and location in the GUSTO-I trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 30(7), 1606–1610. -
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: Results from platelet IIb/IIIa antagonist for the reduction of Acute Coronary Syndrome Events in a Global Organization Network B (PARAGON b)
Mukherjee, D., Mahaffey, K. W., Moliterno, D. J., Harrington, R. A., Yadav, J. S., Pieper, K. S., … Topol, E. J. (2002). Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: Results from platelet IIb/IIIa antagonist for the reduction of Acute Coronary Syndrome Events in a Global Organization Network B (PARAGON b). AMERICAN HEART JOURNAL, 144(6), 995–1002. -
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
Storey, R. F., Kotha, J., Smyth, S. S., Moliterno, D. J., Rorick, T. L., Moccetti, T., … Jennings, L. K. (2014). Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thrombosis and Haemostasis, 111(5), 883–891. -
The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes.
Goyal, A., Petersen, J. L., & Mahaffey, K. W. (2004). The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes. Current Cardiology Reports, 6(4), 300–307. -
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.
Mahaffey, K. W., Lewis, B. E., Wildermann, N. M., Berkowitz, S. D., Oliverio, R. M., Turco, M. A., … Califf, R. M. (2003). The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. Journal of Invasive Cardiology, 15(11), 611–616. -
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).
Hicks, K. A., Tcheng, J. E., Bozkurt, B., Chaitman, B. R., Cutlip, D. E., Farb, A., … Targum, S. L. (2015). 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). Circulation, 132(4), 302–361. -
Clopidogrel and PPI Interaction: Clinically Relevant or Not?
Harrison, R. W., & Mahaffey, K. W. (2012). Clopidogrel and PPI Interaction: Clinically Relevant or Not? CURRENT CARDIOLOGY REPORTS, 14(1). -
Methylmercury exposure and health effects in humans: A worldwide concern
Mergler, D., Anderson, H. A., Chan, L. H. M., Mahaffey, K. R., Murray, M., Sakamoto, M., & Stern, A. H. (2007). Methylmercury exposure and health effects in humans: A worldwide concern. AMBIO, 36(1), 3–11. -
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J. L., Kober, L., Maggioni, A. P., … Lee, C. (2003). Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. NEW ENGLAND JOURNAL OF MEDICINE, 349(20), 1893–1906. -
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial
Pun, P. H., Abdalla, S., Block, G. A., Chertow, G. M., Correa-Rotter, R., Dehmel, B., … Middleton, J. P. (2016). Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial. HEMODIALYSIS INTERNATIONAL, 20(3), 421–31. -
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
Vaduganathan, M., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., … Bhatt, D. L. (2016). Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 9(6). -
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis Results From the TRACER Angiographic Substudy
Popma, C. J., Sheng, S., Korjian, S., Daaboul, Y., Chi, G., Tricoci, P., … Gibson, C. M. (2016). Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis Results From the TRACER Angiographic Substudy. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 9(5). -
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials
Kragholm, K., Goldstein, S. A., Yang, Q., Lopes, R. D., Schulte, P. J., Bernacki, G. M., … Newby, L. K. (2016). Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials. CIRCULATION, 133(16), 1560-? -
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes The TRACER Trial
Vranckx, P., White, H. D., Huang, Z., Mahaffey, K. W., Armstrong, P. W., Van de Werf, F., … Tricoci, P. (2016). Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes The TRACER Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 67(18), 2135–44. -
Management of Patients With NSTE-ACS A Comparison of the Recent AHA/ACC and ESC Guidelines
Rodriguez, F., & Mahaffey, K. W. (2016). Management of Patients With NSTE-ACS A Comparison of the Recent AHA/ACC and ESC Guidelines. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 68(3), 313–21. -
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin Insights From ROCKET AF
Fordyce, C. B., Hellkamp, A. S., Lokhnygina, Y., Lindner, S. M., Piccini, J. P., Becker, R. C., … Patel, M. R. (2016). On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin Insights From ROCKET AF. CIRCULATION, 134(1), 37-? -
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
Breithardt, G., Baumgartner, H., Berkowitz, S. D., Hellkamp, A. S., Piccini, J. P., Lokhnygina, Y., … Patel, M. R. (2016). Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. HEART, 102(13), 1036–43. -
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease
Lopes, R. D., Rao, M., Simon, D. J. N., Thomas, L., Ansell, J., Fonarow, G. C., … Mahaffey, K. W. (2016). Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. AMERICAN JOURNAL OF MEDICINE, 129(6), 592–U197. -
Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
Gundlund, A., Fosbol, E. L., Kim, S., Fonarow, G. C., Gersh, B. J., Kowey, P. R., … Peterson, E. D. (2016). Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. AMERICAN HEART JOURNAL, 175, 28–35. -
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial
Berger, J. S., Katona, B. G., Jones, W. S., Patel, M. R., Norgren, L., Baumgartner, I., … Hiatt, W. R. (2016). Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. AMERICAN HEART JOURNAL, 175, 86–93. -
North American Thrombosis Forum, AF Action Initiative Consensus Document
Ruff, C. T., Ansell, J. E., Becker, R. C., Benjamin, E. J., Deicicchi, D. J., Estes, N. A. M., … Weitz, J. I. (2016). North American Thrombosis Forum, AF Action Initiative Consensus Document. AMERICAN JOURNAL OF MEDICINE, 129(5), S1–S29. -
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Shah, R., Hellkamp, A., Lokhnygina, Y., Becker, R. C., Berkowitz, S. D., Breithardt, G., … Patel, M. R. (2016). Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. American Heart Journal, 179, 77–86. -
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Armaganijan, L. V., Alexander, K. P., Huang, Z., Tricoci, P., Held, C., Van de Werf, F., … Lopes, R. D. (2016). Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. American Heart Journal, 178, 176–84. -
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
O'Brien, E. C., Kim, S., Thomas, L., Fonarow, G. C., Kowey, P. R., Mahaffey, K. W., … Peterson, E. D. (2016). Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. Journal of the American Heart Association, 5(5). -
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial.
Åkerblom, A., Clare, R. M., Lokhnygina, Y., Wallentin, L., Held, C., Van de Werf, F., … Tricoci, P. (2016). Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. American Heart Journal, 178, 1–8. -
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
Sherwood, M. W., Cyr, D. D., Jones, W. S., Becker, R. C., Berkowitz, S. D., Washam, J. B., … Patel, M. R. (2016). Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. JACC. Cardiovascular Interventions, 9(16), 1694–1702. -
Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial.
Vemulapalli, S., Hellkamp, A. S., Jones, W. S., Piccini, J. P., Mahaffey, K. W., Becker, R. C., … Patel, M. R. (2016). Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. American Heart Journal, 178, 74–84. -
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.
Déry, J.-P., Mahaffey, K. W., Tricoci, P., White, H. D., Podder, M., Westerhout, C. M., … Rao, S. V. (2016). Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Catheterization and Cardiovascular Interventions , 88(2), 163–73. -
Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome.
Hess, P. L., Wojdyla, D. M., Al-Khatib, S. M., Lokhnygina, Y., Wallentin, L., Armstrong, P. W., … Tricoci, P. (2016). Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. JAMA Cardiology, 1(1), 73–79. -
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Cavender, M. A., Bhatt, D. L., Stone, G. W., White, H. D., Steg, P. G., Gibson, C. M., … Harrington, R. A. (2016). Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circulation, 134(10), 723–33. -
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF.
DeVore, A. D., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G., Hacke, W., … Piccini, J. P. (2016). Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. Europace , 18(8), 1135–42. -
Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction.
van Diepen, S., Alemayehu, W. G., Zheng, Y., Theroux, P., Newby, L. K., Mahaffey, K. W., … Armstrong, P. W. (2016). Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction. Journal of Thrombosis and Thrombolysis, 42(3), 376–85. -
Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition.
Ungar, L., Rodriguez, F., & Mahaffey, K. W. (2016). Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition. Coronary Artery Disease, 27(7), 604–15. -
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial
Moe, S. M., Abdalla, S., Chertow, G. M., Parfrey, P. S., Block, G. A., Correa-Rotter, R., … Drueeke, T. B. (2015). Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 26(6), 1466–75. -
Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery
Whellan, D. J., Tricoci, P., Chen, E., Huang, Z., Leibowitz, D., Vranckx, P., … Mahaffey, K. W. (2014). Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 63(11), 1048–57. -
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention
Genereux, P., Stone, G. W., Harrington, R. A., Gibson, C. M., Steg, P. G., Brener, S. J., … Bhatt, D. L. (2014). Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 63(7), 619–29. -
Heart Failure Complicating Non-ST-Segment Elevation Acute Coronary Syndrome Timing, Predictors, and Clinical Outcomes
Bahit, M. C., Lopes, R. D., Clare, R. M., Newby, L. K., Pieper, K. S., Van de Werf, F., … Granger, C. B. (2013). Heart Failure Complicating Non-ST-Segment Elevation Acute Coronary Syndrome Timing, Predictors, and Clinical Outcomes. JACC-HEART FAILURE, 1(3), 223–29. -
Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation
Sherwood, M. W., Douketis, J. D., Patel, M. R., Piccini, J. P., Hellkamp, A. S., Lokhnygina, Y., … Becker, R. C. (2014). Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. CIRCULATION, 129(18), 1850–59. -
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial
Shah, R., Hellkamp, A., Lokhnygina, Y., Becker, R. C., Berkowitz, S. D., Breithardt, G., … Patel, M. R. (2016). Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. AMERICAN HEART JOURNAL, 179, 77–86. -
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention The CHAMPION PHOENIX Trial
Abtan, J., Steg, P. G., Stone, G. W., Mahaffey, K. W., Gibson, C. M., Hamm, C. W., … Bhatt, D. L. (2016). Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention The CHAMPION PHOENIX Trial. JACC-CARDIOVASCULAR INTERVENTIONS, 9(18), 1905–1913. -
How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
Steinberg, B. A., Shrader, P., Kim, S., Thomas, L., Fonarow, G. C., Ansell, J., … Piccini, J. P. (2016). How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 181, 145–52. -
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention
Sawlani, N. N., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., … Bhatt, D. L. (2017). Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 10(1). -
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention
Vaduganathan, M., Harrington, R. A., Stone, G. W., Deliargyris, E. N., Steg, P. G., Gibson, C. M., … Bhatt, D. L. (2017). Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 69(2), 176–85. -
Optimising the analysis strategy for the CANVAS Program - a pre-specified plan for the integrated analyses of the CANVAS and CANVAS-R trials.
Neal, B., Perkovic, V., Mahaffey, K. W., Fulcher, G., Erondu, N., Desai, M., … Matthews, D. R. (2017). Optimising the analysis strategy for the CANVAS Program - a pre-specified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes, Obesity & Metabolism. -
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
Hiatt, W. R., Fowkes, F. G. R., Heizer, G., Berger, J. S., Baumgartner, I., Held, P., … Patel, M. R. (2017). Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. NEW ENGLAND JOURNAL OF MEDICINE, 376(1), 32–40. -
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes The ORBIT-AF II Registry
Steinberg, B. A., Shrader, P., Thomas, L., Ansell, J., Fonarow, G. C., Gersh, B. J., … Piccini, J. P. (2016). Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes The ORBIT-AF II Registry. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 68(24), 2597–2604. -
Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation
Pandey, A., Kim, S., Moore, C., Thomas, L., Gersh, B., Allen, L. A., … Fonarow, G. C. (2017). Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. JACC-HEART FAILURE, 5(1), 44–52. -
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease
Jones, W. S., Baumgartner, I., Hiatt, W. R., Heizer, G., Conte, M. S., White, C. J., … Fowkes, F. G. R. (2017). Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. CIRCULATION, 135(3), 241-? -
Relation of Post Coronary Artery Bypass Graft Creatine Kinase-MB Elevations and New Q Waves With Long-Term Cardiovascular Death in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease
Domanski, M., Farkouh, M. E., Zak, V., French, J., Alexander, J. H., Bochenek, A., … Fuster, V. (2016). Relation of Post Coronary Artery Bypass Graft Creatine Kinase-MB Elevations and New Q Waves With Long-Term Cardiovascular Death in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease. AMERICAN JOURNAL OF CARDIOLOGY, 118(11), 1655–60. -
Rejoinder.
Fleming, T. R., DeMets, D. L., Roe, M. T., Wittes, J., Calis, K. A., Vora, A. N., … Ellenberg, S. S. (2017). Rejoinder. Clinical Trials , 1740774516688917-? -
Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation.
Hess, P. L., Kim, S., Fonarow, G. C., Thomas, L., Singer, D. E., Freeman, J. V., … Piccini, J. P. (2016). Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. American Journal of Medicine. -
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience.
Leonardi, S., Lopes, R. D., Steg, P. G., Abnousi, F., Menozzi, A., Prats, J., … Mahaffey, K. W. (2016). Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. European Heart Journal. Acute Cardiovascular Care. -
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
Vaduganathan, M., Harrington, R. A., Stone, G. W., Deliargyris, E. N., Steg, P. G., Gibson, C. M., … Bhatt, D. L. (2017). Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA Cardiology, 2(2), 127–35. -
Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.
Robinson, V. M., Bharucha, D. B., Mahaffey, K. W., Dorian, P., & Kowey, P. R. (2017). Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial. American Heart Journal, 185, 43–51. -
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.
Harskamp, R. E., Clare, R. M., Ambrosio, G., Held, C., Lokhnygina, Y., Moliterno, D. J., … Tricoci, P. (2016). Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. European Heart Journal. Acute Cardiovascular Care. -
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
Neal, B., Perkovic, V., Matthews, D. R., Mahaffey, K. W., Fulcher, G., Meininger, G., … de Zeeuw, D. (2017). Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes, Obesity & Metabolism, 19(3), 387–93. -
Cardioversion and subsequent quality of life and natural history of atrial fibrillation.
Pokorney, S. D., Kim, S., Thomas, L., Fonarow, G. C., Kowey, P. R., Gersh, B. J., … Piccini, J. P. (2017). Cardioversion and subsequent quality of life and natural history of atrial fibrillation. American Heart Journal, 185, 59–66. -
LEFT-VENTRICULAR PERFORMANCE AND REMODELING IN RABBITS AFTER MYOCARDIAL-INFARCTION - EFFECTS OF A THYROID-HORMONE ANALOG
Mahaffey, K. W., Raya, T. E., Pennock, G. D., Morkin, E., & Goldman, S. (1995). LEFT-VENTRICULAR PERFORMANCE AND REMODELING IN RABBITS AFTER MYOCARDIAL-INFARCTION - EFFECTS OF A THYROID-HORMONE ANALOG. CIRCULATION, 91(3), 794–801. -
Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort.
Kittle, J. (2017). Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. Clin Cardiol. 2017 Jun 12., 899–906. -
Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation
Hess, P. L., Kim, S., Fonarow, G. C., Thomas, L., Singer, D. E., Freeman, J. V., … Piccini, J. P. (2017). Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. AMERICAN JOURNAL OF MEDICINE, 130(4), 449–56. -
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.
Hess, C. N., Clare, R. M., Neely, M. L., Tricoci, P., Mahaffey, K. W., James, S. K., … Roe, M. T. (2017). Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. American Heart Journal, 187, 194–203. -
Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
Steinberg, B. A., Simon, D. J. N., Thomas, L., Ansell, J., Fonarow, G. C., Gersh, B. J., … Piccini, J. P. (2017). Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). American Journal of Cardiology, 119(10), 1590–95. -
Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites.
Koshizaka, M., Lopes, R. D., Newby, L. K., Clare, R. M., Schulte, P. J., Tricoci, P., … Alexander, J. H. (2017). Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. The American Journal of Medicine. -
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
Balla, S. R., Cyr, D. D., Lokhnygina, Y., Becker, R. C., Berkowitz, S. D., Breithardt, G., … Patel, M. R. (2017). Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). American Journal of Cardiology, 119(12), 1989–96. -
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial.
Sun, Y., Hu, D., Stevens, S., Lokhnygina, Y., Becker, R. C., Berkowitz, S. D., … Patel, M. R. (2017). Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. Thrombosis Research. -
Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation.
Black-Maier, E., Kim, S., Steinberg, B. A., Fonarow, G. C., Freeman, J. V., Kowey, P. R., … Piccini, J. P. (2017). Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clinical Cardiology. -
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.
Pagidipati, N. J., Hess, C. N., Clare, R. M., Akerblom, A., Tricoci, P., Wojdyla, D., … Roe, M. T. (2017). An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. American Heart Journal, 187, 53–61. -
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial
Valgimigli, M., Costa, F., Lokhnygina, Y., Clare, R. M., Wallentin, L., Moliterno, D. J., … Tricoci, P. (2017). Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. EUROPEAN HEART JOURNAL, 38(11), 804-? -
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
Orgel, R., Wojdyla, D., Huberman, D., Halperin, J. L., Breithardt, G., Singer, D. E., … Patel, M. R. (2017). Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 10(5). -
Adjuvant Antithrombotic Therapy in TAVR
O'Malley, R. G., Mahaffey, K. W., & Fearon, W. F. (2017). Adjuvant Antithrombotic Therapy in TAVR. CURRENT CARDIOLOGY REPORTS, 19(5). -
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
Abnousi, F., Sundaram, V., Yong, C. M., Prats, J., Deliargyris, E. N., Stone, G. W., … Mahaffey, K. W. (2017). Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. American Heart Journal, 188, 147–55. -
Data monitoring committees: Promoting best practices to address emerging challenges
Fleming, T. R., DeMets, D. L., Roe, M. T., Wittes, J., Calis, K. A., Vora, A. N., … Ellenberg, S. S. (2017). Data monitoring committees: Promoting best practices to address emerging challenges. CLINICAL TRIALS, 14(2), 115–23. -
Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]).
Cherian, T. S., Shrader, P., Fonarow, G. C., Allen, L. A., Piccini, J. P., Peterson, E. D., … Mahaffey, K. W. (2017). Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). American Journal of Cardiology, 119(11), 1763–69. -
Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.
Alfredsson, J., Neely, B., Neely, M. L., Bhatt, D. L., Goodman, S. G., Tricoci, P., … Roe, M. T. (2017). Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. Heart (British Cardiac Society). -
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., … Matthews, D. R. (2017). Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine, 377(7), 644–57. -
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
Povsic, T. J., Scott, R., Mahaffey, K. W., Blaustein, R., Edelberg, J. M., Lefkowitz, M. P., … Roe, M. T. (2017). Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. Cardiovascular Drugs and Therapy, 31(4), 445–58. -
A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction
Kahn, J. S., Witteles, R. M., Mahaffey, K. W., Desai, S. A., Ozdalga, E., & Heidenreich, P. A. (2017). A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction. ADVANCES IN MEDICAL EDUCATION AND PRACTICE, 8, 559–66. -
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., … Temple, R. J. (2018). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 71(9), 1021–34. -
Disease understanding in patients newly diagnosed with atrial fibrillation
Kaufman, B. G., Kim, S., Pieper, K., Allen, L. A., Gersh, B. J., Naccarelli, G. V., … O'Brien, E. C. (2018). Disease understanding in patients newly diagnosed with atrial fibrillation. HEART, 104(6), 494–501. -
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., … Perkovic, V. (2017). The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. AMERICAN JOURNAL OF NEPHROLOGY, 46(6), 462–72. -
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., … Matthews, D. R. (2018). Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). CIRCULATION, 137(4), 323–34. -
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program
Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., … Matthews, D. R. (2017). Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS. -
International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries
Steinberg, B. A., Gao, H., Shrader, P., Pieper, K., Thomas, L., Camm, A. J., … Fox, K. A. A. (2017). International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. AMERICAN HEART JOURNAL, 194, 132–40. -
Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry
Melloni, C., Shrader, P., Carver, J., Piccini, J. P., Thomas, L., Fonarow, G. C., … Kowey, P. R. (2017). Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 3(3), 192–97. -
Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry
Fudim, M., Liu, P. R., Shrader, P., Blanco, R. G., Allen, L. A., Fonarow, G. C., … Piccini, J. P. (2018). Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 7(8). -
Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)
Thomas, K. L., Jackson, L. R., Shrader, P., Ansell, J., Fonarow, G. C., Gersh, B., … Peterson, E. D. (2017). Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation). JOURNAL OF THE AMERICAN HEART ASSOCIATION, 6(12). -
Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
Steinberg, B. A., Shrader, P., Pieper, K., Thomas, L., Allen, L. A., Ansell, J., … Piccini, J. P. (2018). Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). JOURNAL OF THE AMERICAN HEART ASSOCIATION, 7(4). -
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Groves, E. M., Bhatt, D. L., Steg, P. G., Deliargyris, E. N., Stone, G. W., Gibson, C. M., … Price, M. J. (2018). Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circulation. Cardiovascular Interventions, 11(4), e005635. -
Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention Findings From CHAMPION PHOENIX
Cavender, M. A., Bhatt, D. L., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., … Harrington, R. A. (2017). Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention Findings From CHAMPION PHOENIX. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 10(8). -
Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention
Tricoci, P., Newby, L. K., Clare, R. M., Leonardi, S., Gibson, C. M., Giugliano, R. P., … White, H. D. (2018). Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. JACC-CARDIOVASCULAR INTERVENTIONS, 11(9), 856-+. -
THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL
Olivier, C., Abnousi, F., Sundaram, V., Yang, J., Stone, G., Steg, P., … Yong, C. (2018). THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 71(11), 29. -
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials
Eisen, A., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., … Bhatt, D. L. (2018). Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. INTERNATIONAL JOURNAL OF CARDIOLOGY, 250, 49–55. -
Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials
Vaduganathan, M., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., … Bhatt, D. L. (2018). Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. EUROINTERVENTION, 13(15), 1841–49. -
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
Guimaraes, P. O., Leonardi, S., Huang, Z., Wallentin, L., Van de Werf, F., Aylward, P. E., … Tricoci, P. (2018). Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. AMERICAN HEART JOURNAL, 196, 28–35. -
Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation).
Barnett, A. S., Kim, S., Fonarow, G. C., Thomas, L. E., Reiffel, J. A., Allen, L. A., … Piccini, J. P. (2017). Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). Circulation. Arrhythmia and Electrophysiology, 10(11). -
External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction
Williams, B. A., Chagin, K. M., Bash, L. D., Boden, W. E., Duval, S., Fowkes, F. G. R., … Bonaca, M. P. (2018). External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. ATHEROSCLEROSIS, 272, 80–86. -
Initiating anticoagulation with the intention of cardioverting: does drug choice matter?
Mahaffey, K. W., & Turakhia, M. P. (2018). Initiating anticoagulation with the intention of cardioverting: does drug choice matter? European Heart Journal. -
Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome
Olivier, C. B., Turakhia, M. P., & Mahaffey, K. W. (2018). Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. EXPERT OPINION ON DRUG SAFETY, 17(3), 251–58. -
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial
Kochar, A., Hellkamp, A. S., Lokhnygina, Y., Jones, W. S., Becker, R. C., Berkowitz, S. D., … Patel, M. R. (2018). Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. CLINICAL CARDIOLOGY, 41(1), 39–45. -
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., … Temple, R. J. (2018). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. CIRCULATION, 137(9), 961–72. -
Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study
Storey, R. F., Ardissino, D., Vignali, L., Cairns, R., Becker, R. C., Cannon, C. P., … Wallentin, L. (2018). Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. THROMBOSIS AND HAEMOSTASIS, 118(2), 427–29. -
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
Leef, G. C., Hellkamp, A. S., Patel, M. R., Becker, R. C., Berkowitz, S. D., Breithardt, G., … Piccini, J. P. (2017). Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 6(6). -
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF
Barnett, A. S., Cyr, D. D., Goodman, S. G., Levitan, B. S., Yuan, Z., Hankey, G. J., … Piccini, J. P. (2018). Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. INTERNATIONAL JOURNAL OF CARDIOLOGY, 257, 78–83. -
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
Chen, S. T., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fox, K. A. A., … Patel, M. R. (2017). Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). AMERICAN JOURNAL OF CARDIOLOGY, 120(10), 1837–40. -
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial
Norgren, L., Patel, M. R., Hiatt, W. R., Wojdyla, D. M., Fowkes, F. G. R., Baumgartner, I., … Bjoerck, M. (2018). Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 55(1), 109–17. -
Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis
Bagai, A., Alexander, K. P., Berger, J. S., Senior, R., Sajeev, C., Pracon, R., … Chaitman, B. R. (2017). Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. AMERICAN HEART JOURNAL, 190, 135–39. -
Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials.
Olivier, C. B., Sundaram, V., Bhatt, D. L., Leonardi, S., Lopes, R. D., Ding, V. Y., … Mahaffey, K. W. (2018). Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. International Journal of Cardiology. -
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review
Radholm, K., Wu, J. H. Y., Wong, M. G., Foote, C., Fulcher, G., Mahaffey, K. W., … Neal, B. (2018). Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review. DIABETES RESEARCH AND CLINICAL PRACTICE, 140, 118–28. -
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF
Chen, S. T., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fox, K. A. A., … Patel, M. R. (2018). Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. AMERICAN HEART JOURNAL, 200, 102–9. -
Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction
Rymer, J. A., Tempelhof, M. W., Clare, R. M., Pieper, K. S., Granger, C. B., Van de Werf, F., … Newby, L. K. (2018). Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction. AMERICAN HEART JOURNAL, 201, 103–10. -
Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome
Inohara, T., Pieper, K., Wojdyla, D. M., Patel, M. R., Jones, W. S., Tricoci, P., … Vemulapalli, S. (2018). Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. AMERICAN HEART JOURNAL, 201, 25–32. -
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis
Scirica, B. M., Bansilal, S., Davoudi, F., Armstrong, P. W., Clare, R. M., Schulte, P. J., … Cannon, C. P. (2018). Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. AMERICAN HEART JOURNAL, 202, 54–60. -
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Radholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., … Neal, B. (2018). Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. CIRCULATION, 138(5), 458–68. -
Association of Healthcare Plan with Atrial Fibrillation Prescription Patterns.
Chang, A. Y., Askari, M., Fan, J., Heidenreich, P. A., Ho, P. M., Mahaffey, K. W., … Turakhia, M. P. (2018). Association of Healthcare Plan with Atrial Fibrillation Prescription Patterns. Clinical Cardiology. -
Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery
Mehta, R. H., Leimberger, J. D., van Diepen, S., Meza, J., Wang, A., Jankowich, R., … Alexander, J. H. (2017). Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. NEW ENGLAND JOURNAL OF MEDICINE, 376(21), 2032–42. -
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial
Tricoci, P., Neely, M., Whitley, M. J., Edelstein, L. C., Simon, L. M., Shaw, C., … Bray, P. F. (2018). Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. BLOOD CELLS MOLECULES AND DISEASES, 72, 37–43. -
Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"
Matthews, D. R., Perkovic, V., & Mahaffey, K. W. (2018). Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist". CIRCULATION, 138(6), 660–61. -
Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation
O'Brien, E. C., Holmes, D. J. N., Thomas, L. E., Fonarow, G. C., Allen, L. A., Gersh, B. J., … Hylek, E. M. (2018). Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. CIRCULATION, 138(9), 889–97. -
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondu, N., Shaw, W., … Neal, B. (2018). Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. LANCET DIABETES & ENDOCRINOLOGY, 6(9), 691–704. -
Optimised care of elderly patients with acute coronary syndrome
Leonardi, S., Bueno, H., Ahrens, I., Hassager, C., Bonnefoy, E., & Lettino, M. (2018). Optimised care of elderly patients with acute coronary syndrome. EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, 7(3), 287–95. -
Academic health centers: integration of clinical research with healthcare and education. Comments on a workshop.
Arai, R. J., Noronha, I. de, Nicolau, J. C., Schmidt, C., de Albuquerque, G. M., Mahaffey, K. W., … Auler Junior, J. O. (2018). Academic health centers: integration of clinical research with healthcare and education. Comments on a workshop. Clinics (Sao Paulo, Brazil), 73(suppl 1), e515s. -
Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization
Baumgartner, I., Norgren, L., Fowkes, F. G. R., Mulder, H., Patel, M. R., Berger, J. S., … Hiatt, W. R. (2018). Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 72(14), 1563–72. -
Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
Jackson, L. R., Kim, S., Shrader, P., Blanco, R., Thomas, L., Ezekowitz, M. D., … Piccini, J. P. (2018). Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 46(4), 435–39. -
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., … Perkovic, V. (2018). Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program. CIRCULATION, 138(15), 1537–50. -
Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2-VASc Scores: Findings From the ORBIT-AF I and II Registries.
Jackson, L. R., Kim, S., Fonarow, G. C., Freeman, J. V., Gersh, B. J., Go, A. S., … Piccini, J. P. (2018). Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2-VASc Scores: Findings From the ORBIT-AF I and II Registries. Journal of the American Heart Association, 7(16), e008764. -
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF.
Washam, J. B., Holmes, D. J. N., Thomas, L. E., Pokorney, S. D., Hylek, E. M., Fonarow, G. C., … Piccini, J. P. (2018). Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF. Journal of the American Heart Association, 7(18), e008928. -
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.
Quinn, G. R., Hellkamp, A. S., Hankey, G. J., Becker, R. C., Berkowitz, S. D., Breithardt, G., … Singer, D. E. (2018). Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. Journal of the American Heart Association, 7(15), e008755. -
Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study.
Turakhia, M. P., Desai, M., Hedlin, H., Rajmane, A., Talati, N., Ferris, T., … Perez, M. V. (2018). Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. American Heart Journal. -
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., … Zeiher, A. M. (2018). Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. The New England Journal of Medicine. -
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial.
Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., … Steg, P. G. (2018). Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial. Journal of the American College of Cardiology. -
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.
Lindholm, D., James, S. K., Gabrysch, K., Storey, R. F., Himmelmann, A., Cannon, C. P., … Wallentin, L. (2018). Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study. JAMA Cardiology. -
Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.
Essien, U. R., Holmes, D. J. N., Jackson, L. R., Fonarow, G. C., Mahaffey, K. W., Reiffel, J. A., … Singer, D. E. (2018). Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiology. -
Reviewing the role of healthy volunteer studies in drug development.
Karakunnel, J. J., Bui, N., Palaniappan, L., Schmidt, K. T., Mahaffey, K. W., Morrison, B., … Kummar, S. (2018). Reviewing the role of healthy volunteer studies in drug development. Journal of Translational Medicine, 16(1), 336. -
Incremental prognostic value of renal function for stroke prediction in atrial fibrillation
O'Brien, E. C., Holmes, D. J. N., Thomas, L., Singer, D. E., Fonarow, G. C., Mahaffey, K. W., … Piccini, J. P. (2019). Incremental prognostic value of renal function for stroke prediction in atrial fibrillation. INTERNATIONAL JOURNAL OF CARDIOLOGY, 274, 152–57. -
Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation
Durheim, M. T., Holmes, D. J. N., Blanco, R. G., Allen, L. A., Chan, P. S., Freeman, J. V., … Piccini, J. P. (2018). Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. HEART, 104(22), 1850–58. -
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10854 patients from the CHAMPION PHOENIX trial.
Stone, G. W., Genereux, P., Harrington, R. A., White, H. D., Gibson, C. M., Steg, P. G., … Bhatt, D. L. (2018). Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10854 patients from the CHAMPION PHOENIX trial. European Heart Journal, 39(46), 4112–21. -
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial.
Ungar, L., Clare, R. M., Rodriguez, F., Kolls, B. J., Armstrong, P. W., Aylward, P., … Melloni, C. (2018). Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. Journal of the American Heart Association, 7(24), e009609. -
Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.
Olivier, C. B., Mulder, H., Hiatt, W. R., Jones, W. S., Fowkes, F. G., Rockhold, F. W., … Mahaffey, K. W. (2018). Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. JAMA Cardiology. -
Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial.
Abtan, J., Ducrocq, G., Steg, P. G., Stone, G. W., Mahaffey, K. W., Gibson, C. M., … Bhatt, D. L. (2018). Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. International Journal of Cardiology. -
Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry)
Thind, M., Holmes, D. N., Badri, M., Pieper, K. S., Singh, A., Blanco, R. G., … Kowey, P. R. (2018). Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). AMERICAN JOURNAL OF CARDIOLOGY, 122(10), 1677–83. -
International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee
Mok, Y., Ballew, S. H., Bash, L. D., Bhatt, D. L., Boden, W. E., Bonaca, M. P., … Matsushita, K. (2018). International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 7(14). -
Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF
O'Brien, E. C., Holmes, D. N., Thomas, L., Fonarow, G. C., Kowey, P. R., Ansell, J. E., … Hylek, E. M. (2018). Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 7(12). -
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
Held, C., White, H. D., Stewart, R. A., Davies, R., Sampson, S., Chiswell, K., … Wallentin, L. (2018). Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. American Heart Journal, 208, 65–73. -
Cardiovascular and Limb Outcomes in Patients With Diabetes and PeripheralArtery Disease: The EUCLID Trial.
Low Wang, C. C., Blomster, J. I., Heizer, G., Berger, J. S., Baumgartner, I., Fowkes, F. G., … Hiatt, W. R. (2018). Cardiovascular and Limb Outcomes in Patients With Diabetes and PeripheralArtery Disease: The EUCLID Trial. Journal of the American College of Cardiology, 72(25), 3274–84. -
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial
Berger, J. S., Abramson, B. L., Lopes, R. D., Heizer, G., Rockhold, F. W., Baumgartner, I., … Mahaffey, K. W. (2018). Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. VASCULAR MEDICINE, 23(6), 523–30. -
Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9,259 Deaths in 9 Trials.
Fanaroff, A. C., Clare, R., Pieper, K. S., Mahaffey, K. W., Melloni, C., Green, J., … Lopes, R. D. (2018). Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9,259 Deaths in 9 Trials. Circulation. -
Canagliflozin and Stroke in Type 2 Diabetes Mellitus.
Zhou, Z., Lindley, R. I., Radholm, K., Jenkins, B., Watson, J., Perkovic, V., … Neal, B. (2018). Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke, STROKEAHA118023009. -
Alirocumab Reduces Risk of Death after Acute Coronary Syndrome in Patients with Persistently Elevated Atherogenic Lipoproteins on Intensive Statin Treatment
Schwartz, G. G., Szarek, M. M., Bhatt, D. L., Bittner, V. A., Bregeault, M.-F., Dalby, A. J., … Steg, P. G. (2018). Alirocumab Reduces Risk of Death after Acute Coronary Syndrome in Patients with Persistently Elevated Atherogenic Lipoproteins on Intensive Statin Treatment. CIRCULATION, 138(25), E772–E773. -
Cost-Effectiveness of Alirocumab Based on Evidence From a Large Multinational Outcome Trial: The ODYSSEY OUTCOMES Economics Study
Bhatt, D. L., Briggs, A., Reed, S. D., Annemans, L., Szarek, M., Bittner, V. A., … Steg, G. (2018). Cost-Effectiveness of Alirocumab Based on Evidence From a Large Multinational Outcome Trial: The ODYSSEY OUTCOMES Economics Study. CIRCULATION, 138(25), E753–E754. -
Canagliflozin review - safety and efficacy profile in patients with T2DM
Jakher, H., Chang, T. I., Tan, M., & Mahaffey, K. W. (2019). Canagliflozin review - safety and efficacy profile in patients with T2DM. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 12, 209–15. -
Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration.
Leef, G. C., Perino, A. C., Askari, M., Fan, J., Ho, P. M., Olivier, C. B., … Turakhia, M. P. (2019). Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration. Journal of Pharmacy Practice, 897190019828270. -
Characteristics of Digital Health Studies Registered in ClinicalTrials.gov.
Chen, C. E., Harrington, R. A., Desai, S. A., Mahaffey, K. W., & Turakhia, M. P. (2019). Characteristics of Digital Health Studies Registered in ClinicalTrials.gov. JAMA Internal Medicine. -
Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry).
Vemulapalli, S., Inohara, T., Kim, S., Thomas, L., Piccini, J. P., Patel, M. R., … Peterson, E. D. (2019). Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). The American Journal of Cardiology. -
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.
Matthews, D. R., Li, Q., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., … Neal, B. (2019). Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia. -
Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment.
Abtan, J., Ducrocq, G., Steg, P. G., Stone, G. W., Mahaffey, K. W., Gibson, C. M., … Bhatt, D. L. (2019). Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment. Circulation. Cardiovascular Interventions, 12(3), e007445. -
EFFICACY OF A CENTRALIZED, BLENDED ELECTRONIC, AND HUMAN INTERVENTION TO IMPROVE DOAC ADHERENCE: THE SMARTADHERE TRIAL
Turakhia, M. P., Sundaram, V., Smith, S., Ding, V., Ho, P. M., Kowey, P. R., … Mahaffey, K. (2019). EFFICACY OF A CENTRALIZED, BLENDED ELECTRONIC, AND HUMAN INTERVENTION TO IMPROVE DOAC ADHERENCE: THE SMARTADHERE TRIAL. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC. -
Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program.
Figtree, G. A., Radholm, K., Barrett, T. D., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., … Neal, B. (2019). Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program. Circulation. -
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation.
Inohara, T., Kim, S., Pieper, K., Blanco, R. G., Allen, L. A., Fonarow, G. C., … Piccini, J. P. (2018). B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. Heart (British Cardiac Society). -
Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF.
Chen, S. T., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fox, K. A., … Melloni, C. (2018). Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF. European Heart Journal. Quality of Care & Clinical Outcomes. -
Rhythm Control Versus Rate Control andClinical Outcomes in Patients WithAtrial Fibrillation: Results From the ORBIT-AF Registry.
Noheria, A., Shrader, P., Piccini, J. P., Fonarow, G. C., Kowey, P. R., Mahaffey, K. W., … Gersh, B. J. (2016). Rhythm Control Versus Rate Control andClinical Outcomes in Patients WithAtrial Fibrillation: Results From the ORBIT-AF Registry. JACC. Clinical Electrophysiology, 2(2), 221–29. -
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)
Vaduganathan, M., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., … Bhatt, D. L. (2017). Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). AMERICAN JOURNAL OF CARDIOLOGY, 120(7), 1043–48. -
Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes ORBIT-AF Registry
Echouffo-Tcheugui, J. B., Shrader, P., Thomas, L., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., … Fonarow, G. C. (2017). Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes ORBIT-AF Registry. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 70(11), 1325–35. -
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial)
Washam, J. B., Hellkamp, A. S., Lokhnygina, Y., Piccini, J. P., Berkowitz, S. D., Nessel, C. C., … Patel, M. R. (2017). Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). AMERICAN JOURNAL OF CARDIOLOGY, 120(4), 588–94. -
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Steinberg, B. A., Shrader, P., Thomas, L., Ansell, J., Fonarow, G. C., Gersh, B. J., … Piccini, J. P. (2017). Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). AMERICAN HEART JOURNAL, 189, 40–47. -
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study
Parker, W. A., Bhatt, D. L., Prats, J., Day, J. R. S., Steg, P. G., Stone, G. W., … Storey, R. F. (2017). Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. THROMBOSIS AND HAEMOSTASIS, 117(6), 1093–1100. -
CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF UNFRACTIONATED HEPARIN INSIGHTS FROM CHAMPION PHOENIX
Vaduganathan, M., Harrington, R., Stone, G., Steg, P., Gibson, C. M., Hamm, C., … Bhatt, D. (2017). CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF UNFRACTIONATED HEPARIN INSIGHTS FROM CHAMPION PHOENIX. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 69(11), 1345. -
IMPACT OF PERIPROCEDURAL MYOCARDIAL INFARCTION IN CONTEMPORARY PCI: POOLED PATIENT-LEVEL DATA FROM THE CHAMPION TRIALS
Vaduganathan, M., Harrington, R., Stone, G., Steg, P., Gibson, C. M., Hamm, C., … Bhatt, D. (2017). IMPACT OF PERIPROCEDURAL MYOCARDIAL INFARCTION IN CONTEMPORARY PCI: POOLED PATIENT-LEVEL DATA FROM THE CHAMPION TRIALS. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 69(11), 112. -
ONE-YEAR MORTALITY INCREASED IN PATIENTS WITH PERI-PROCEDURAL MYOCARDIAL INFARCTION: INSIGHTS FROM THE CHAMPION TRIALS
Olivier, C., Sundaram, V., Ding, V., Yang, L., Leonardi, S., Lopes, R., … Mahaffey, K. (2017). ONE-YEAR MORTALITY INCREASED IN PATIENTS WITH PERI-PROCEDURAL MYOCARDIAL INFARCTION: INSIGHTS FROM THE CHAMPION TRIALS. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC. -
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis
Lindner, S. M., Fordyce, C. B., Hellkamp, A. S., Lokhnygina, Y., Piccini, J. P., Breithardt, G., … Patel, M. R. (2017). Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. CIRCULATION, 135(10), 1001–3. -
Effects of Ticagrelor Compared With Clopidogrel in Patients With Peripheral Artery Disease (EUCLID)
Patel, M. R., Fowkes, F. G. R., Berger, J. S., Norgren, L., Heizer, G., Baumgartner, I., … Hiatt, W. R. (2016). Effects of Ticagrelor Compared With Clopidogrel in Patients With Peripheral Artery Disease (EUCLID). CIRCULATION, 134(25), E703. -
Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling
Pokorney, S. D., Shrader, P., Thomas, L., Fonarow, G. C., Kowey, P. R., Singer, D. E., … Peterson, E. D. (2016). Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. CIRCULATION, 134(15), 1122–24. -
Association of Body Mass Index WithCareand Outcomes in Patients WithAtrialFibrillation: Results From the ORBIT-AF Registry.
Pandey, A., Gersh, B. J., McGuire, D. K., Shrader, P., Thomas, L., Kowey, P. R., … Fonarow, G. C. (2016). Association of Body Mass Index WithCareand Outcomes in Patients WithAtrialFibrillation: Results From the ORBIT-AF Registry. JACC. Clinical Electrophysiology, 2(3), 355–63. -
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"
Piccini, J. P., Hellkamp, A. S., Washam, J. B., Becker, R. C., Breithardt, G., Berkowitz, S. D., … Patel, M. R. (2016). Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". CIRCULATION, 134(2), E7–E8. -
THE EFFICACY AND SAFETY OF CANGRELOR WITH AND WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POOLED ANALYSIS OF THE CHAMPION TRIALS
Vaduganathan, M., Harrington, R., Stone, G., Steg, P., Gibson, C. M., Hamm, C., … Bhatt, D. (2016). THE EFFICACY AND SAFETY OF CANGRELOR WITH AND WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POOLED ANALYSIS OF THE CHAMPION TRIALS. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 67(13), 452. -
Efficacy of Cangrelor in Lesions with High-Risk and Low-Risk Angiographic Characteristics: The CHAMPION PHOENIX trial
Stone, G. W., Genereux, P., White, H. D., Gibson, C. M., Hamm, C., Mahaffey, K., … Bhatt, D. L. (2015). Efficacy of Cangrelor in Lesions with High-Risk and Low-Risk Angiographic Characteristics: The CHAMPION PHOENIX trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 66(15), B36–B37. -
Cangrelor Improves Ischemic Outcomes In Patients With Multivessel Disease And Single Vessel Disease Undergoing PCI: Insights From The CHAMPION PHOENIX Trial
Abnousi, F., Sundaram, V., Prats, J., Deliargyris, E. N., Stone, G. W., Hamm, C., … Mahaffey, K. (2015). Cangrelor Improves Ischemic Outcomes In Patients With Multivessel Disease And Single Vessel Disease Undergoing PCI: Insights From The CHAMPION PHOENIX Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC. -
Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX
Bhatt, D. L., Stone, G. W., Mahaffey, K., Gibson, C. M., Steg, P. G., Hamm, C., … Harrington, R. (2014). Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 64(11), B142. -
REDUCED DEATH, MYOCARDIAL INFARCTION, AND EARLY STENT THROMBOSIS WITH CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF BIVALIRUDIN: INSIGHTS FROM CHAMPION PHOENIX
White, H. D., Bhatt, D. L., Gibson, C. M., Hamm, C. W., Mahaffey, K. W., Price, M. J., … Harrington, R. A. (2014). REDUCED DEATH, MYOCARDIAL INFARCTION, AND EARLY STENT THROMBOSIS WITH CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF BIVALIRUDIN: INSIGHTS FROM CHAMPION PHOENIX. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 63(12), A36. -
Heart Failure is Associated With Worse Quality of Life and Survival But Similar Stroke Risk in Atrial Fibrillation
Cherian, T. S., Shrader, P., Fonarow, G. C., Allen, L. A., Peterson, E. D., Piccini, J., … Mahaffey, K. W. (2015). Heart Failure is Associated With Worse Quality of Life and Survival But Similar Stroke Risk in Atrial Fibrillation. JOURNAL OF CARDIAC FAILURE. CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS. -
Cardiac Safety Research Consortium (CSRC): Cardiovascular Safety and Adverse Event Case Report Forms
Sabol, M. E., Finkle, J., Krucoff, M., Stockbridge, N., Parkhill, N., Shinagawa, K., … Oh, R. (2015). Cardiac Safety Research Consortium (CSRC): Cardiovascular Safety and Adverse Event Case Report Forms. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 49(4), 511–13. -
No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: Challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014
Wallentin, L., Becker, R. C., Cannon, C. P., Held, C., Himmelmann, A., Husted, S., … Harrington, R. A. (2014). No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: Challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. INTERNATIONAL JOURNAL OF CARDIOLOGY, 176(1), 300–302. -
Response to Letter Regarding Article, "Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial"
Steg, P. G., Harrington, R. A., Emanuelsson, H., Katus, H. A., Mahaffey, K. W., Meier, B., … James, S. K. (2014). Response to Letter Regarding Article, "Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial". CIRCULATION, 129(19), E494–E495. -
Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Peripheral Artery Disease: Results From TRACER
Jones, S., Tricoci, P., Huang, Z., Moliterno, D. J., Harrington, R. A., Sinnaeve, P., … Mahaffey, K. W. (2013). Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Peripheral Artery Disease: Results From TRACER. CIRCULATION, 128(22). -
CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS: Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial
Tricoci, P., Chen, E., Neely, M. L., Warner, A., Wong, P. H., Sinnaeve, P., … Moliterno, D. J. (2013). CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS: Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial. CIRCULATION, 128(22). -
Evolution of Differences in Women and Men With Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From Clinical Trials Over 15 Years
Halim, S., Yang, Q., Schulte, P., Hochman, J., Melloni, C., Mahaffey, K. W., … Newby, L. K. (2013). Evolution of Differences in Women and Men With Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From Clinical Trials Over 15 Years. CIRCULATION, 128(22). -
Differential Prognostic Implications of Peak Troponin Level in Acute Coronary Syndrome Treated With and Without Revascularization
Bagai, A., Huang, Z., Lokhnygina, Y., Harrington, R. A., Armstrong, P. W., Strony, J., … Mahaffey, K. W. (2013). Differential Prognostic Implications of Peak Troponin Level in Acute Coronary Syndrome Treated With and Without Revascularization. CIRCULATION, 128(22). -
Efficacy and Safety of Vorapaxar in Elderly Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Insights From the TRACER Trial
Armaganijan, L., Lopes, R., Huang, Z., Tricoci, P., Held, C., Van de Werf, F., … Mahaffey, K. W. (2013). Efficacy and Safety of Vorapaxar in Elderly Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Insights From the TRACER Trial. CIRCULATION, 128(22). -
Arterial Access Site and Outcomes in Patients Undergoing Percutaneous Coronary Intervention With and Without Vorapaxar
Dery, J.-P. P., Mahaffey, K., Tricoci, P., White, H., Podder, M., Moliterno, D., … Rao, S. (2013). Arterial Access Site and Outcomes in Patients Undergoing Percutaneous Coronary Intervention With and Without Vorapaxar. CIRCULATION, 128(22). -
Trends in Enrollment, Patient Characteristics, Treatments and Outcomes of Older Adults With Non-ST-segment Elevation Acute Coronary Syndromes (ACS) in Clinical Trials
Bernacki, G. M., Alexander, K. P., Newby, L. K., Yang, Q., Schulte, P., White, H. D., … Lopes, R. D. (2013). Trends in Enrollment, Patient Characteristics, Treatments and Outcomes of Older Adults With Non-ST-segment Elevation Acute Coronary Syndromes (ACS) in Clinical Trials. CIRCULATION, 128(22). -
Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation.
Madhavan, M., Holmes, D. J. N., Piccini, J. P., Ansell, J. E., Fonarow, G. C., Hylek, E. M., … Gersh, B. J. (2019). Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. American Heart Journal, 211, 77–89. -
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J., Charytan, D. M., … Mahaffey, K. W. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine. -
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Schwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., … Steg, P. G. (2014). Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. American Heart Journal, 168(5), 682–9. -
Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study).
Yong, C., Azarbal, F., Abnousi, F., Heidenreich, P. A., Schmitt, S., Fan, J., … Turakhia, M. P. (2016). Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study). The American Journal of Cardiology, 117(1), 61–8. -
Canagliflozin review - safety and efficacy profile in patients with T2DM.
Jakher, H., Chang, T. I., Tan, M., & Mahaffey, K. W. (2019). Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, 12, 209–215. -
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.
O'Donoghue, M. L., Bhatt, D. L., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., … Harrington, R. A. (2016). Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. Circulation, 133(3), 248–55. -
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Tricoci, P., Lokhnygina, Y., Huang, Z., Van de Werf, F., Cornel, J. H., Chen, E., … Mahaffey, K. W. (2014). Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. American Heart Journal, 168(6), 869–77.e1. -
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).
Jones, W. S., Tricoci, P., Huang, Z., Moliterno, D. J., Harrington, R. A., Sinnaeve, P. R., … Mahaffey, K. W. (2014). Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). American Heart Journal, 168(4), 588–96. -
Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation).
Thomas, K. L., Jackson, L. R., Shrader, P., Ansell, J., Fonarow, G. C., Gersh, B., … Peterson, E. D. (2017). Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation). Journal of the American Heart Association, 6(12). -
International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.
Steinberg, B. A., Gao, H., Shrader, P., Pieper, K., Thomas, L., Camm, A. J., … Fox, K. A. (2017). International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal, 194, 132–140. -
Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease.
McCrindle, B. W., Li, J. S., Manlhiot, C., Tweddell, J. S., Giglia, T. M., Massicotte, M. P., … Kaltman, J. R. (2014). Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease. Circulation, 130(14), 1192–203. -
Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial.
Gutierrez, J. A., Mulder, H., Jones, W. S., Rockhold, F. W., Baumgartner, I., Berger, J. S., … Patel, M. R. (2018). Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. JAMA Network Open, 1(7), e185239. -
Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist".
Matthews, D. R., Perkovic, V., & Mahaffey, K. W. (2018). Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist". Circulation, 138(6), 660–661. -
Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort.
Kittle, J., Lopes, R. D., Huang, M., Marquess, M. L., Wilson, M. D., Ascher, J., … Mahaffey, K. W. (2017). Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. Clinical Cardiology, 40(10), 899–906. -
Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium.
Seltzer, J. H., Turner, J. R., Geiger, M. J., Rosano, G., Mahaffey, K. W., White, W. B., … Sager, P. T. (2015). Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium. American Heart Journal, 169(2), 197–204. -
Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.
Varenhorst, C., Alström, U., Braun, O. Ö., Storey, R. F., Mahaffey, K. W., Bertilsson, M., … Held, C. (2014). Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart (British Cardiac Society), 100(22), 1762–9. -
Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry.
Perino, A. C., Shrader, P., Turakhia, M. P., Ansell, J. E., Gersh, B. J., Fonarow, G. C., … Mahaffey, K. W. (2019). Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry. Journal of the American Heart Association, 8(9), e011205. -
Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation
Madhavan, M., Holmes, D. J. N., Piccini, J. P., Ansell, J. E., Fonarow, G. C., Hylek, E. M., … Gersh, B. J. (2019). Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. AMERICAN HEART JOURNAL, 211, 77–89. -
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., … Zeiher, A. M. (2018). Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. NEW ENGLAND JOURNAL OF MEDICINE, 379(22), 2097–2107. -
Stroke in Patients With Peripheral Artery Disease.
Kolls, B. J., Sapp, S., Rockhold, F. W., Jordan, J. D., Dombrowski, K. E., Fowkes, F. G., … Patel, M. R. (2019). Stroke in Patients With Peripheral Artery Disease. Stroke, STROKEAHA118023534. -
Association of Healthcare Plan with atrial fibrillation prescription patterns
Chang, A. Y., Askari, M., Fan, J., Heidenreich, P. A., Ho, P. M., Mahaffey, K. W., … Turakhia, M. P. (2018). Association of Healthcare Plan with atrial fibrillation prescription patterns. CLINICAL CARDIOLOGY, 41(9), 1136–43. -
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
White, H. D., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., … Schwartz, G. G. (2019). Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal. -
Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Brégeault, M.-F. F., Dalby, A. J., … Schwartz, G. G. (2019). Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation. -
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
Matthews, D. R., Li, Q., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., … Neal, B. (2019). Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. DIABETOLOGIA, 62(6), 926–38. -
Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II.
Inohara, T., Shrader, P., Pieper, K., Blanco, R. G., Allen, L. A., Fonarow, G. C., … Piccini, J. P. (2019). Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. American Heart Journal, 213, 81–90. -
Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study
Turakhia, M. P., Desai, M., Hedlin, H., Rajmane, A., Talati, N., Ferris, T., … Perez, M. V. (2019). Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. AMERICAN HEART JOURNAL, 207, 66–75. -
Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry)
Vemulapalli, S., Inohara, T., Kim, S., Thomas, L., Piccini, J. P., Patel, M. R., … Peterson, E. D. (2019). Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). AMERICAN JOURNAL OF CARDIOLOGY, 123(10), 1628–36. -
Canagliflozin and Stroke in Type 2 Diabetes Mellitus Results From the Randomized CANVAS Program Trials
Zhou, Z., Lindley, R. I., Radholm, K., Jenkins, B., Watson, J., Perkovic, V., … Neal, B. (2019). Canagliflozin and Stroke in Type 2 Diabetes Mellitus Results From the Randomized CANVAS Program Trials. STROKE, 50(2), 396–404. -
Characteristics of Digital Health Studies Registered in ClinicalTrials.gov
Chen, C. E., Harrington, R. A., Desai, S. A., Mahaffey, K. W., & Turakhia, M. P. (2019). Characteristics of Digital Health Studies Registered in ClinicalTrials.gov. JAMA INTERNAL MEDICINE, 179(6), 838–40. -
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation
Inohara, T., Kim, S., Pieper, K., Blanco, R. G., Allen, L. A., Fonarow, G. C., … Piccini, J. P. (2019). B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. HEART, 105(5), 370–77. -
Stroke in Patients With Peripheral Artery Disease: Insights From the EUCLID Study
Kolls, B. J., Sapp, S., Rockhold, F. W., Jordan, J. D., Dombrowski, K. E., Fowkes, F. G. R., … Patel, M. R. (2019). Stroke in Patients With Peripheral Artery Disease: Insights From the EUCLID Study. STROKE, 50(6), 1356–63. -
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., … Mahaffey, K. W. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. NEW ENGLAND JOURNAL OF MEDICINE, 380(24), 2295–2306. -
Acute Limb Ischemia in Peripheral Artery Disease: Insights from EUCLID.
Hess, C. N., Huang, Z., Patel, M. R., Baumgartner, I., Berger, J. S., Blomster, J. I., … Hiatt, W. R. (2019). Acute Limb Ischemia in Peripheral Artery Disease: Insights from EUCLID. Circulation. -
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKETAF
Chen, S. T., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fox, K. A. A., … Melloni, C. (2019). Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKETAF. EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 5(2), 145–52. -
Reviewing the role of healthy volunteer studies in drug development
Karakunnel, J. J., Bui, N., Palaniappan, L., Schmidt, K. T., Mahaffey, K. W., Morrison, B., … Kummar, S. (2018). Reviewing the role of healthy volunteer studies in drug development. JOURNAL OF TRANSLATIONAL MEDICINE, 16. -
The efficacy and safety of cangrelor in single vessel vs multi vessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX.
Yong, C. M., Sundaram, V., Abnousi, F., Olivier, C. B., Yang, J., Stone, G. W., … Mahaffey, K. W. (2019). The efficacy and safety of cangrelor in single vessel vs multi vessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. Clinical Cardiology. -
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
Pokorney, S. D., Holmes, D. J. N., Thomas, L., Fonarow, G. C., Kowey, P. R., Reiffel, J. A., … Peterson, E. D. (2019). Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiology. -
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., … Steg, P. G. (2019). Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet. Diabetes & Endocrinology. -
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.
Olivier, C. B., Bhatt, D. L., Leonardi, S., Stone, G. W., Gibson, C. M., Steg, P. G., … Mahaffey, K. W. (2019). Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. Circulation. Cardiovascular Interventions, 12(7), e007342. -
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial.
Mahaffey, K. W., Jardine, M. J., Bompoint, S., Cannon, C. P., Neal, B., Heerspink, H. J., … Perkovic, V. (2019). Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial. Circulation. -
Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial.
Hopley, C. W., Kavanagh, S., Patel, M. R., Ostrom, C., Baumgartner, I., Berger, J. S., … Hiatt, W. R. (2019). Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. Vascular Medicine (London, England), 1358863X19864172. -
A Cluster Analysis of the Japanese Multicenter Outpatient Registry of Patients With Atrial Fibrillation.
Inohara, T., Piccini, J. P., Mahaffey, K. W., Kimura, T., Katsumata, Y., Tanimoto, K., … Kohsaka, S. (2019). A Cluster Analysis of the Japanese Multicenter Outpatient Registry of Patients With Atrial Fibrillation. The American Journal of Cardiology. -
Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF.
Ungar, L., Rodriguez, F., Hellkamp, A. S., Becker, R. C., Berkowitz, S. D., Breithardt, G., … Mahaffey, K. W. (2019). Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. Cardiology and Therapy. -
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
Zhou, Z., Jardine, M., Perkovic, V., Matthews, D. R., Mahaffey, K. W., de Zeeuw, D., … Neal, B. (2019). Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia. -
Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention.
Olivier, C. B., Fan, J., Askari, M., Mahaffey, K. W., Heidenreich, P. A., Perino, A. C., … Turakhia, M. P. (2019). Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. Circulation. Cardiovascular Interventions, 12(8), e007604. -
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program
Figtree, G. A., Radholm, K., Barrett, T. D., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., … Neal, B. (2019). Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program. CIRCULATION, 139(22), 2591–93. -
Factors Associated With Patient-Reported Shared Decision-Making for Stroke Prevention in Atrial Fibrillation
O'Brien, E. C., Pieper, K., Thiem, R., Fonarow, G. C., Kowey, P. R., Chan, P. S., … Piccini, J. P. (2019). Factors Associated With Patient-Reported Shared Decision-Making for Stroke Prevention in Atrial Fibrillation. STROKE. LIPPINCOTT WILLIAMS & WILKINS. -
Cardiovascular Risk Factors and Secondary Events Among Acute and Chronic Stable Myocardial Infarction Patients: Findings from a Managed Care Database.
Bash, L. D., White, K., Patel, M. D., Liu, J., Mavros, P., & Mahaffey, K. W. (2019). Cardiovascular Risk Factors and Secondary Events Among Acute and Chronic Stable Myocardial Infarction Patients: Findings from a Managed Care Database. Cardiology and Therapy. -
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial
Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., … Mohamed, W. M. I. W. (2019). Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 73(4), 387–96. -
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Roe, M. T., Li, Q. H., Bhatt, D. L., Bittner, V. A., Diaz, R., Goodman, S. G., … Schwartz, G. G. (2019). Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. -
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Neuen, B. L., Young, T., Heerspink, H. J., Neal, B., Perkovic, V., Billot, L., … Jardine, M. J. (2019). SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. The Lancet. Diabetes & Endocrinology. -
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial
Jukema, J. W., Szarek, M., Zijlstra, L. E., de Silva, H. A., Bhatt, D. L., Bittner, V. A., … Steg, P. G. (2019). Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 74(9), 1167–76. -
Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply.
Jardine, M. J., Mahaffey, K. W., & Perkovic, V. (2019). Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply. The New England Journal of Medicine, 381(11), 1089–90. -
Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT-AF Registry
Perino, A. C., Shrader, P., Turakhia, M. P., Ansell, J. E., Gersh, B. J., Fonarow, G. C., … Mahaffey, K. W. (2019). Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT-AF Registry. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 8(9). -
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.
Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., … Perkovic, V. (2019). Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. Journal of the American Society of Nephrology : JASN. -
Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials
Fanaroff, A. C., Clare, R., Pieper, K. S., Mahaffey, K. W., Melloni, C., Green, J. B., … Lopes, R. D. (2019). Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. CIRCULATION, 139(7), 863–73. -
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial
Held, C., White, H. D., Stewart, R. A. H., Davies, R., Sampson, S., Chiswell, K., … Wallentin, L. (2019). Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. AMERICAN HEART JOURNAL, 208, 65–73. -
Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease The EUCLID Trial
Wang, C. C. L., Blomster, J. I., Heizer, G., Berger, J. S., Baumgartner, I., Fowkes, F. G. R., … Hiatt, W. R. (2018). Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease The EUCLID Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 72(25), 3274–84. -
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPIONPHOENIX trial
Stone, G. W., Genereux, P., Harrington, R. A., White, H. D., Gibson, C. M., Steg, P. G., … Bhatt, D. L. (2018). Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPIONPHOENIX trial. EUROPEAN HEART JOURNAL, 39(46), 4112–21. -
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
Ungar, L., Clare, R. M., Rodriguez, F., Kolls, B. J., Armstrong, P. W., Aylward, P., … Melloni, C. (2018). Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 7(24). -
Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease Insights From the EUCLID Trial
Olivier, C. B., Mulder, H., Hiatt, W. R., Jones, W. S., Fowkes, F. G. R., Rockhold, F. W., … Mahaffey, K. W. (2019). Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease Insights From the EUCLID Trial. JAMA CARDIOLOGY, 4(1), 7–15. -
Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II
Essien, U. R., Holmes, D. J. N., Jackson, L. R., Fonarow, G. C., Mahaffey, K. W., Reiffel, J. A., … Singer, D. E. (2018). Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA CARDIOLOGY, 3(12), 1174–82. -
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial
Quinn, G. R., Hellkamp, A. S., Hankey, G. J., Becker, R. C., Berkowitz, S. D., Breithardt, G., … Singer, D. E. (2018). Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 7(15). -
Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA(2)DS(2)-VASc Scores: Findings From the ORBIT-AF I and II Registries
Jackson, L. R., Kim, S., Fonarow, G. C., Freeman, J. V., Gersh, B. J., Go, A. S., … Piccini, J. P. (2018). Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA(2)DS(2)-VASc Scores: Findings From the ORBIT-AF I and II Registries. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 7(16). -
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF
Washam, J. B., Holmes, D. J. N., Thomas, L. E., Pokorney, S. D., Hylek, E. M., Fonarow, G. C., … Piccini, J. P. (2018). Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 7(18). -
Academic health centers: integration of clinical research with healthcare and education. Comments on a workshop
Arai, R. J., Noronha, I. de L., Nicolau, J. C., Schmidt, C., de Albuquerque, G. M., Mahaffey, K. W., … Costa Auler Junior, J. O. (2018). Academic health centers: integration of clinical research with healthcare and education. Comments on a workshop. CLINICS, 73. -
Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials
Olivier, C. B., Sundaram, V., Bhatt, D. L., Leonardi, S., Lopes, R. D., Ding, V. Y., … Mahaffey, K. W. (2018). Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. INTERNATIONAL JOURNAL OF CARDIOLOGY, 270, 96–101. -
Initiating anticoagulation with the intention of cardioverting: does drug choice matter?
Mahaffey, K. W., & Turakhia, M. P. (2018). Initiating anticoagulation with the intention of cardioverting: does drug choice matter? EUROPEAN HEART JOURNAL, 39(32), 2972–74. -
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
Groves, E. M., Bhatt, D. L., Steg, P. G., Deliargyris, E. N., Stone, G. W., Gibson, C. M., … Price, M. J. (2018). Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 11(4). -
Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation)
Barnett, A. S., Kim, S., Fonarow, G. C., Thomas, L. E., Reiffel, J. A., Allen, L. A., … Piccini, J. P. (2017). Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 10(11). -
The Association of Health-Related Quality-of-Life Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID Trial
Rymer, J., Mulder, H., Smolderen, K., Hiatt, W., Conte, M., Berger, J., … Patel, M. (2019). The Association of Health-Related Quality-of-Life Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 74(13), B547. -
Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial.
Kansal, A., Huang, Z., Rockhold, F. W., Baumgartner, I., Berger, J. S., Blomster, J. I., … Jones, W. S. (2019). Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial. Circulation. Cardiovascular Interventions, 12(10), e008069. -
Open versus Endovascular Repair of Abdominal Aortic Aneurysm REPLY
Jardine, M. J., Mahaffey, K. W., & Perkovic, V. (2019). Open versus Endovascular Repair of Abdominal Aortic Aneurysm REPLY. NEW ENGLAND JOURNAL OF MEDICINE, 381(11), 1089–90. -
Mediators of the Effects of Canagliflozin on HeartFailure in Patients With Type 2 Diabetes.
Li, J. W., Woodward, M., Perkovic, V., Figtree, G. A., Heerspink, H. J., Mahaffey, K. W., … Neal, B. (2019). Mediators of the Effects of Canagliflozin on HeartFailure in Patients With Type 2 Diabetes. JACC. Heart Failure. -
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.
Loring, Z., Shrader, P., Allen, L. A., Blanco, R., Chan, P. S., Ezekowitz, M. D., … Piccini, J. P. (2019). Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. American Heart Journal, 219, 21–30. -
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.
Cannon, C. P., Perkovic, V., Agarwal, R., Baldassarre, J., Bakris, G., Charytan, D. M., … Mahaffey, K. W. (2019). Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial. Circulation. -
Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation.
Perez, M. V., Mahaffey, K. W., Hedlin, H., Rumsfeld, J. S., Garcia, A., Ferris, T., … Turakhia, M. P. (2019). Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. The New England Journal of Medicine, 381(20), 1909–17. -
Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials.
Brennan, J. M., Wruck, L., Pencina, M. J., Clare, R. M., Lopes, R. D., Alexander, J. H., … Peterson, E. D. (2019). Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. American Heart Journal, 218, 110–22. -
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.
Ohkuma, T., Van Gaal, L., Shaw, W., Mahaffey, K. W., de Zeeuw, D., Matthews, D. R., … Neal, B. (2019). Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. Diabetes, Obesity & Metabolism. -
Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
Sharma, A., Wu, J., Ezekowitz, J. A., Felker, G. M., Udell, J. A., Heidenreich, P. A., … DeVore, A. D. (2019). Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure. ESC Heart Failure. -
EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER
Perkovic, V., Bain, S., Bakris, G., Buse, J., Gondolf, T., Idorn, T., … Mann, J. (2019). EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER. NEPHROLOGY DIALYSIS TRANSPLANTATION, 34. -
EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS
Perkovic, V., Bain, S., Bakris, G., Buse, J., Idorn, T., Mahaffey, K., … Mann, J. (2019). EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. NEPHROLOGY DIALYSIS TRANSPLANTATION, 34, 338. -
EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER
Perkovic, V., Bain, S., Bakris, G., Buse, J., Idorn, T., Mahaffey, K., … Mann, J. (2019). EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. NEPHROLOGY DIALYSIS TRANSPLANTATION, 34, 205–U715. -
DIFFERENT EGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM
Oshima, M., Ohkuma, T., Neal, B., Li, Q., De Zeeuw, D., Mahaffey, K. W., … Perkovic, V. (2019). DIFFERENT EGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM. NEPHROLOGY DIALYSIS TRANSPLANTATION, 34, 206. -
A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation.
Olivier, C. B., Sundaram, V., Chertow, G. M., Shashidhar, S., McDonnell, L. K., Ding, V. Y., … Mell, M. (2019). A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation. The Journal of Vascular Access, 1129729819887269. -
Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial.
Ward, R., Huang, Z., Rockhold, F. W., Baumgartner, I., Berger, J. S., Blomster, J. I., … Jones, W. S. (2019). Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. American Heart Journal, 220, 51–58. -
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation.
Pokorney, S. D., Holmes, D. J. N., Shrader, P., Thomas, L., Fonarow, G. C., Mahaffey, K. W., … Reiffel, J. A. (2019). Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal, 220, 145–54. -
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation.
Freeman, J. V., Shrader, P., Pieper, K. S., Allen, L. A., Chan, P. S., Fonarow, G. C., … Piccini, J. P. (2019). Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Circulation. Arrhythmia and Electrophysiology, 12(12), e007612. -
Cohort profile: patient characteristics and quality-of-life measurements for newly-referred patients with atrial fibrillation-Keio interhospital Cardiovascular Studies-atrial fibrillation (KiCS-AF).
Ikemura, N., Spertus, J. A., Kimura, T., Mahaffey, K., Piccini, J. P., Inohara, T., … Kohsaka, S. (2019). Cohort profile: patient characteristics and quality-of-life measurements for newly-referred patients with atrial fibrillation-Keio interhospital Cardiovascular Studies-atrial fibrillation (KiCS-AF). BMJ Open, 9(12), e032746. -
Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation.
Inohara, T., Holmes, D. J. N., Pieper, K., Blanco, R. G., Allen, L. A., Fonarow, G. C., … Piccini, J. P. (2020). Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart (British Cardiac Society). -
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Arnott, C., Li, Q., Kang, A., Neuen, B. L., Bompoint, S., Lam, C. S., … Neal, B. (2020). Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 9(3), e014908. -
Apixaban versus Warfarin for Stroke Prevention in Patients With End Stage Renal Disease on Hemodialysis and Atrial Fibrillation: Results of a Randomized Clinical Trial Assessing Safety
Pokorney, S. D., Chertow, G. M., Al-Khalidi, H., Gallup, D., Dignacco, P., Mussina, K., … Granger, C. B. (2019). Apixaban versus Warfarin for Stroke Prevention in Patients With End Stage Renal Disease on Hemodialysis and Atrial Fibrillation: Results of a Randomized Clinical Trial Assessing Safety. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS. -
Apple Watch App Identifies Clinically Important Arrhythmias Other Than Atrial Fibrillation: Results From the Apple Heart Study
Perez, M. V., Mahaffey, K., Hedlin, H., Rumsfeld, J. S., Garcia, A., Ferris, T., … Turakhia, M. (2019). Apple Watch App Identifies Clinically Important Arrhythmias Other Than Atrial Fibrillation: Results From the Apple Heart Study. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS. -
Amino-Terminal Pro-B Type Natriuretic Peptide in the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program
Januzzi, J. L., Xu, J., Shaw, W., Oh, R., Ranadive, G., Butler, J., … Hansen, M. K. (2019). Amino-Terminal Pro-B Type Natriuretic Peptide in the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program. CIRCULATION, 140(25), E996. -
Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease.
Haine, A., Kavanagh, S., Berger, J. S., Hess, C. N., Norgren, L., Fowkes, F. G., … Baumgartner, I. (2020). Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease. Journal of the American College of Cardiology, 75(6), 608–17. -
Cangrelor in clinical use.
Feng, K. Y., & Mahaffey, K. W. (2020). Cangrelor in clinical use. Future Cardiology. -
Diabetes and heart failure post-acute myocardial infarction: Important associations and need for evidence-based interventions.
Parizo, J., & Mahaffey, K. W. (2020). Diabetes and heart failure post-acute myocardial infarction: Important associations and need for evidence-based interventions. European Journal of Preventive Cardiology, 2047487320904232. -
Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation.
Dalgaard, F., North, R., Pieper, K., Fonarow, G. C., Kowey, P. R., Gersh, B. J., … Piccini, J. P. (2020). Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. American Heart Journal, 223, 65–71. -
Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY.
Rhee, J. J., Jardine, M. J., Chertow, G. M., & Mahaffey, K. W. (2020). Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Diabetes, Obesity & Metabolism, 22 Suppl 1, 46–54. -
Factors Associated with Large Improvements in Health-Related Quality of Life in Patients with Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
Steinberg, B. A., Holmes, D. J. N., Pieper, K., Allen, L. A., Chan, P. S., Ezekowitz, M. D., … Piccini, J. P. (2020). Factors Associated with Large Improvements in Health-Related Quality of Life in Patients with Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation. Arrhythmia and Electrophysiology. -
Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus.
Granger, C. B., & Mahaffey, K. W. (2020). Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus. Circulation, 141(15), 1235–37. -
Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events.
Fanaroff, A. C., Haque, G., Thomas, B., Stone, A. E., Perkins, L. M., Wilson, M., … Lopes, R. D. (2020). Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events. Trials, 21(1), 323. -
CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS
Sarraju, A., Li, J. W., Cannon, C. P., Chang, T. I., Agarwal, R., Bakris, G. L., … Mahaffey, K. W. (2020). CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC. -
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Jardine, M. J., Zhou, Z., Mahaffey, K. W., Oshima, M., Agarwal, R., Bakris, G., … Perkovic, V. (2020). Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology : JASN, 31(5), 1128–39. -
Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive IPAH and COVID-19 Infection.
Zamanian, R. T., Pollack, C. V., Gentile, M. A., Rashid, M., Fox, J. C., Mahaffey, K. W., & de Jesus Perez, V. (2020). Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive IPAH and COVID-19 Infection. American Journal of Respiratory and Critical Care Medicine. -
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
Bhatt, D. L., Briggs, A. H., Reed, S. D., Annemans, L., Szarek, M., Bittner, V. A., … Gabriel Steg, P. (2020). Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. Journal of the American College of Cardiology, 75(18), 2297–2308. -
Incremental value of diastolic stress test in identifying subclinical heart failure in patients with diabetes mellitus.
Nishi, T., Kobayashi, Y., Christle, J. W., Cauwenberghs, N., Boralkar, K., Moneghetti, K., … Haddad, F. (2020). Incremental value of diastolic stress test in identifying subclinical heart failure in patients with diabetes mellitus. European Heart Journal Cardiovascular Imaging. -
Shared Decision Making in Atrial Fibrillation: Patient-Reported Involvement in Treatment Decisions.
Ali-Ahmed, F., Pieper, K., North, R., Allen, L. A., Chan, P. S., Ezekowitz, M. D., … O'Brien, E. C. (2020). Shared Decision Making in Atrial Fibrillation: Patient-Reported Involvement in Treatment Decisions. European Heart Journal. Quality of Care & Clinical Outcomes. -
Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry.
Sherwood, M. W., Piccini, J. P., Holmes, D. J. N., Pieper, K. S., Steinberg, B. A., Fonarow, G. C., … Rao, S. V. (2020). Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry. Circulation. Cardiovascular Interventions, 13(5), e008274. -
The effect of canagliflozin on amputation risk in the CANVAS Program and the CREDENCE trial.
Arnott, C., Huang, Y., Neuen, B., Di Tanna, G. L., Cannon, C. P., Oh, R., … Neal, B. (2020). The effect of canagliflozin on amputation risk in the CANVAS Program and the CREDENCE trial. Diabetes, Obesity & Metabolism. -
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.
Li, J. W., Neal, B., Perkovic, V., de Zeeuw, D., Neuen, B. L., Arnott, C., … Heerspink, H. J. (2020). Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney International. -
Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Jackson, L. R., Kim, S., Blanco, R., Thomas, L., Ansell, J., Fonarow, G. C., … Piccini, J. P. (2020). Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). American Heart Journal, 226, 85–93. -
The Project Baseline Health Study: a step towards a broader mission to map human health
Arges, K., Assimes, T., Bajaj, V., Balu, S., Bashir, M. R., Beskow, L., … Wong, C. A. (2020). The Project Baseline Health Study: a step towards a broader mission to map human health. NPJ DIGITAL MEDICINE, 3(1), 84. -
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.
Arnott, C., Neuen, B. L., Heerspink, H. J., Figtree, G. A., Kosiborod, M., Lam, C. S., … Neal, B. (2020). The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. International Journal of Cardiology. -
Patterns of oral anticoagulation use with cardioversion in clinical practice.
Geurink, K., Holmes, D. J., Ezekowitz, M. D., Pieper, K., Fonarow, G., Kowey, P. R., … Pokorney, S. D. (2020). Patterns of oral anticoagulation use with cardioversion in clinical practice. Heart (British Cardiac Society). -
Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.
Long, C. A., Mulder, H., Fowkes, F. G., Baumgartner, I., Berger, J. S., Katona, B. G., … Nehler, M. R. (2020). Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. Circulation. Cardiovascular Quality and Outcomes, CIRCOUTCOMES119006399. -
Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI.
Marquis-Gravel, G., Dalgaard, F., Jones, A. D., Lokhnygina, Y., James, S. K., Harrington, R. A., … Roe, M. T. (2020). Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. Journal of the American College of Cardiology, 76(2), 162–71. -
A Call for a New Paradigm for Diabetes Care in the Era of Sodium-Glucose Cotransporter2 Inhibitors (SGLT2i).
Kim, S. H., Chang, T. I., & Mahaffey, K. W. (2020). A Call for a New Paradigm for Diabetes Care in the Era of Sodium-Glucose Cotransporter2 Inhibitors (SGLT2i). Cardiology and Therapy. -
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.
Oshima, M., Neal, B., Toyama, T., Ohkuma, T., Li, Q., de Zeeuw, D., … Perkovic, V. (2020). Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. Journal of the American Society of Nephrology : JASN. -
Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.
Matthews, D. R., Wysham, C., Davies, M., Slee, A., Alba, M., Lee, M., … Neal, B. (2020). Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program. Diabetes, Obesity & Metabolism. -
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program
Li, J. W., Badve, S., Zhou, Z., Rodgers, A., Day, R., Oh, R., … Neal, B. (2019). The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. LANCET RHEUMATOLOGY, 1(4), E220–E228. -
Estimation of Stroke Outcomes in Atrial Fibrillation Using Continuous Clinical and Implantable Device Data From the Treat-AF Study: A Comparison With CHA2DS2-VASc Score
Bentley, J. P., Askari, M., Fan Jun, Heidenreich, P. A., Mahaffey, K. W., Desai, M., … Turakhia, M. P. (2018). Estimation of Stroke Outcomes in Atrial Fibrillation Using Continuous Clinical and Implantable Device Data From the Treat-AF Study: A Comparison With CHA2DS2-VASc Score. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS. -
Comparing Treatments and Outcomes Across the Spectrum of Stroke and Bleeding Risks in Non-Valvular Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Marzec, L. N., Piccini, J. P., Shrader, P., Pieper, K., Blanco, R. G., Fonarow, G. C., … Allen, L. A. (2018). Comparing Treatments and Outcomes Across the Spectrum of Stroke and Bleeding Risks in Non-Valvular Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS. -
Treatment Patterns and Clinical Outcomes in Adults With Concomitant Atrial Fibrillation and Vascular Disease
Inohara, T., Shrader, P., Pieper, K., Blanco, R. G., Fonarow, G. C., Mahaffey, K. W., … Piccini, J. P. (2018). Treatment Patterns and Clinical Outcomes in Adults With Concomitant Atrial Fibrillation and Vascular Disease. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS. -
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial
Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., … Steg, P. G. (2018). Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS. -
Comparison of Patient Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT-AF Registry
Perino, A. C., Shrader, P., Turakhia, M. P., Ansell, J. E., Gersh, B. J., Fonarow, G. C., … Mahaffey, K. W. (2018). Comparison of Patient Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT-AF Registry. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS. -
Stroke Outcomes With Vorapaxar versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
Ungar, L., Clare, R., Rodriguez, F., Kolls, B., Armstrong, P., Aylward, P., … Melloni, C. (2018). Stroke Outcomes With Vorapaxar versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS. -
The TIMI Risk Score for Secondary Prevention for Myocardial Infarction Applied to Patients With Peripheral Artery Disease: A Collaborative Analysis for the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee
Mok, Y., Ballew, S. H., Bash, L. D., Bhatt, D. L., Bonaca, M. P., Carrero, J. J., … Matsushita, K. (2018). The TIMI Risk Score for Secondary Prevention for Myocardial Infarction Applied to Patients With Peripheral Artery Disease: A Collaborative Analysis for the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS. -
Acute Limb Ischemia in Peripheral Artery Disease: Insights From EUCLID
Hess, C. N., Huang, Z., Patel, M. R., Baumgartner, I., Berger, J. S., Blomster, J., … Hiatt, W. R. (2018). Acute Limb Ischemia in Peripheral Artery Disease: Insights From EUCLID. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS. -
Canagliflozin and cardiovascular outcomes in Type 2 diabetes.
Sarraju, A., Spencer-Bonilla, G., Rodriguez, F., & Mahaffey, K. W. (2020). Canagliflozin and cardiovascular outcomes in Type 2 diabetes. Future Cardiology. -
Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF).
Madhavan, M., Holmes, D. J. N., Piccini, J. P., Freeman, J. V., Fonarow, G. C., Hylek, E. M., … Gersh, B. J. (2020). Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). The American Journal of Cardiology. -
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants A Report of the American College of Cardiology Solution Set Oversight Committee
Tomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., … Wiggins, B. S. (2020). 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants A Report of the American College of Cardiology Solution Set Oversight Committee. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 76(5), 594–622. -
Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial.
Fudim, M., Hopley, C. W., Huang, Z., Kavanagh, S., Rockhold, F. W., Baumgartner, I., … Hiatt, W. R. (2020). Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial. Circulation. Cardiovascular Quality and Outcomes, CIRCOUTCOMES120006512. -
CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL
Kang, A., Neuen, B., Heerspink, H. L., Di Tanna, G. L., Neal, B., Zhang, H., … Jardine, M. (2020). CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL. NEPHROLOGY DIALYSIS TRANSPLANTATION, 35, 1336. -
CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL
Kang, A., Smyth, B., Neuen, B., Heerspink, H. L., Di Tanna, G. L., Neal, B., … Jardine, M. (2020). CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL. NEPHROLOGY DIALYSIS TRANSPLANTATION, 35, 1342. -
EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM
Young, T., Li, J.-wei, Kang, A., Heerspink, H., Hockham, C., Arnott, C., … Jardine, M. (2020). EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM. NEPHROLOGY DIALYSIS TRANSPLANTATION, 35, 1351. -
Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial.
Rymer, J. A., Mulder, H., Smolderen, K. G., Hiatt, W. R., Conte, M. S., Berger, J. S., … Patel, M. R. (2020). Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial. Journal of the American Heart Association, e016573. -
CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.
Gutierrez, J. A., Heizer, G. M., Jones, W. S., Rockhold, F. W., Mahaffey, K. W., Fowkes, F. G., … Patel, M. R. (2020). CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. American Heart Journal, 229, 118–20. -
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., … Wheeler, D. C. (2020). Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. -
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
Yu, J., Zhou, Z., Mahaffey, K. W., Matthews, D. R., Neuen, B. L., Heerspink, H. J., … Arnott, C. (2020). An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. International Journal of Cardiology. -
International consensus definitions of clinical trial outcomes for kidney failure: 2020.
Levin, A., Agarwal, R., Herrington, W. G., Heerspink, H. L., Mann, J. F., Shahinfar, S., … Perkovic, V. (2020). International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney International, 98(4), 849–59. -
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial.
Oshima, M., Neuen, B. L., Li, J. W., Perkovic, V., Charytan, D. M., de Zeeuw, D., … Heerspink, H. J. (2020). Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial. Journal of the American Society of Nephrology : JASN. -
SGLT2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes.
Neuen, B. L., Arnott, C., Perkovic, V., Figtree, G., de Zeeuw, D., Fulcher, G., … Heerspink, H. J. (2020). SGLT2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes, Obesity & Metabolism. -
Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.
Rymer, J. A., Mulder, H., Narcisse, D. I., Rockhold, F., Hiatt, W. R., Fowkes, F. G., … Patel, M. R. (2020). Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. Circulation. Cardiovascular Interventions, CIRCINTERVENTIONS120009326. -
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
Oshima, M., Neuen, B. L., Jardine, M. J., Bakris, G., Edwards, R., Levin, A., … Heerspink, H. J. (2020). Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. The Lancet. Diabetes & Endocrinology, 8(11), 903–14. -
Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
Januzzi, J. L., Xu, J., Li, J. W., Shaw, W., Oh, R., Pfeifer, M., … Hansen, M. K. (2020). Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction. Journal of the American College of Cardiology, 76(18), 2076–85. -
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial
Oshima, M., Neuen, B. L., Jardine, M. J., Bakris, G., Edwards, R., Levin, A., … Heerspink, H. J. L. (2020). Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. LANCET DIABETES & ENDOCRINOLOGY, 8(11), 903–14. -
Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study.
Januzzi, J. L., Butler, J., Sattar, N., Xu, J., Shaw, W., Rosenthal, N., … Hansen, M. K. (2020). Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study. Diabetes Care. -
Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.
Kochar, A., Mulder, H., Rockhold, F. W., Baumgartner, I., Berger, J. S., Blomster, J. I., … Jones, W. S. (2020). Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. Circulation. Cardiovascular Quality and Outcomes, CIRCOUTCOMES120006550. -
Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration
Leef, G. C., Perino, A. C., Askari, M., Fan, J., Ho, P. M., Olivier, C. B., … Turakhia, M. P. (2020). Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration. JOURNAL OF PHARMACY PRACTICE, 33(5), 647–53. -
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
Bakris, G., Oshima, M., Mahaffey, K. W., Agarwal, R., Cannon, C. P., Capuano, G., … Perkovic, V. (2020). Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clinical Journal of the American Society of Nephrology : CJASN. -
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
Oshima, M., Jardine, M. J., Agarwal, R., Bakris, G., Cannon, C. P., Charytan, D. M., … Heerspink, H. J. (2020). Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney International. -
Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial.
Sarraju, A., Li, J. W., Cannon, C. P., Chang, T. I., Agarwal, R., Bakris, G., … Mahaffey, K. W. (2020). Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial. American Heart Journal. -
The ARREST Pneumonia (Arrest Respiratory Failure due to Pneumonia) Trial: Rationale and Design.
Levitt, J. E., Festic, E., Desai, M., Hedlin, H., Mahaffey, K. W., Rogers, A. J., … Matthay, M. A. (2021). The ARREST Pneumonia (Arrest Respiratory Failure due to Pneumonia) Trial: Rationale and Design. Annals of the American Thoracic Society. -
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial.
Ye, N., Jardine, M. J., Oshima, M., Hockham, C., Heerspink, H. J., Agarwal, R., … Neuen, B. L. (2021). Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial. Circulation. -
Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Enrolled in Latin America: Insights from ROCKET AF.
Blumer, V., Rivera, M., Corbalán, R., Becker, R. C., Berkowitz, S. D., Breithardt, G., … Patel, M. R. (2021). Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Enrolled in Latin America: Insights from ROCKET AF. American Heart Journal. -
The Project Baseline Health Study: a step towards a broader mission to map human health.
Arges, K., Assimes, T., Bajaj, V., Balu, S., Bashir, M. R., Beskow, L., … Wong, C. A. (2020). The Project Baseline Health Study: a step towards a broader mission to map human health. NPJ Digital Medicine, 3(1), 84. -
Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus
Feng, K. Y., Gogate, J., Damaraju, C. V., Li, J. W., Jardine, M. J., Perkovic, V., … Mahaffey, K. W. (2021). Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus. METABOLISM-CLINICAL AND EXPERIMENTAL. W B SAUNDERS CO-ELSEVIER INC. -
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.
Yu, J., Arnott, C., Neuen, B. L., Heersprink, H. L., Mahaffey, K. W., Cannon, C. P., … Huffman, M. D. (2021). Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Failure. -
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
Jardine, M., Zhou, Z., Lambers Heerspink, H. J., Hockham, C., Li, Q., Agarwal, R., … Perkovic, V. (2021). Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clinical Journal of the American Society of Nephrology : CJASN. -
Efficacy of a Centralized, Blended Electronic and Human Intervention to Improve Direct Oral Anticoagulant Adherence: Smartphones to improve rivaroxaban ADHEREnce in Atrial Fibrillation (SmartADHERE) A Randomized Clinical Trial: SmartADHERE rivaroxaban adherence trial.
Turakhia, M., Sundaram, V., Smith, S. N., Ding, V., Michael Ho, P., Kowey, P. R., … Mahaffey, K. W. (2021). Efficacy of a Centralized, Blended Electronic and Human Intervention to Improve Direct Oral Anticoagulant Adherence: Smartphones to improve rivaroxaban ADHEREnce in Atrial Fibrillation (SmartADHERE) A Randomized Clinical Trial: SmartADHERE rivaroxaban adherence trial. American Heart Journal. -
The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the CREDENCE Trial.
Arnott, C., Li, J.-W., Cannon, C. P., de Zeeuw, D., Neuen, B. L., Heerspink, H. J., … Mahaffey, K. W. (2021). The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the CREDENCE Trial. Diabetes, Obesity & Metabolism. -
Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II).
Jackson, L. R., Schrader, P., Thomas, L., Steinberg, B. A., Blanco, R., Allen, L. A., … Piccini, J. P. (2021). Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions. -
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.
Yu, J., Li, J., Leaver, P. J., Arnott, C., Huffman, M. D., Udell, J. A., … Figtree, G. A. (2021). Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial. Cardiovascular Research. -
Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial.
Galani, J., Mulder, H., Rockhold, F. W., Weissler, E. H., Baumgartner, I., Berger, J. S., … Jones, W. S. (2021). Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. International Journal of Chronic Obstructive Pulmonary Disease, 16, 841–51. -
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Zhou, Z., Jardine, M. J., Li, Q., Neuen, B. L., Cannon, C. P., de Zeeuw, D., … Lindley, R. I. (2021). Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis. Stroke, STROKEAHA120031623. -
Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID.
Samsky, M. D., Hellkamp, A., Hiatt, W. R., Fowkes, F. G., Baumgartner, I., Berger, J. S., … Jones, W. S. (2021). Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. Journal of the American Heart Association, e018684. -
Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial.
Hsia, J., Kavanagh, S. T., Hopley, C. W., Baumgartner, I., Berger, J. S., Fowkes, G. R., … Bonaca, M. P. (2021). Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. Vascular Medicine (London, England), 1358863X211017641. -
Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial.
Hiatt, W. R., Hess, C. N., Bonaca, M. P., Kavanagh, S., Patel, M. R., Baumgartner, I., … Fowkes, F. G. (2021). Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. Circulation. Cardiovascular Interventions, CIRCINTERVENTIONS120009871. -
Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program.
Wang, K. M., Li, J. W., Bhalla, V., Jardine, M. J., Neal, B., de Zeeuw, D., … Chang, T. I. (2021). Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program. Endocrinology, Diabetes & Metabolism, 4(3), e00247. -
Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials.
Goyal, A., Schibler, T., Alhanti, B., Hannan, K. L., Granger, C. B., Blazing, M. A., … Jones, W. S. (2021). Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. JAMA Network Open, 4(7), e2117963. -
Return of individual research results: What do participants prefer and expect?
Sayeed, S., Califf, R., Green, R., Wong, C., Mahaffey, K., Gambhir, S. S., … Wong, C. A. (2021). Return of individual research results: What do participants prefer and expect? PloS One, 16(7), e0254153. -
Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.
Jensen, I. S., Wu, E., Cyr, P. L., Claussen, M., Winkler, T., Salahuddin, K., … Bhatt, D. L. (2021). Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective. American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions. -
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF.
Ugowe, F. E., Hellkamp, A. S., Wang, A., Becker, R. C., Berkowitz, S. D., Breithardt, G., … Piccini, J. P. (2021). Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF. Heart Rhythm O2, 2(3), 215–222. -
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
Sen, T., Li, J., Neuen, B. L., Neal, B., Arnott, C., Parikh, C. R., … Heerspink, H. J. (2021). Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia. -
Reasons for hospitalizations in patients with type 2 diabetes mellitus in the CANVAS Program: a secondary analysis.
Feng, K. Y., Li, J. W., Ianus, J., de Zeeuw, D., Fulcher, G. R., Pfeifer, M., … Mahaffey, K. W. (2021). Reasons for hospitalizations in patients with type 2 diabetes mellitus in the CANVAS Program: a secondary analysis. Diabetes, Obesity & Metabolism. -
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
Neuen, B. L., Oshima, M., Perkovic, V., Agarwal, R., Arnott, C., Bakris, G., … Heerspink, H. J. (2021). Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. European Heart Journal.
-
Comparison of Site-Reported and Core Laboratory-Reported Creatine Kinase-MB Values in Non-ST-Segment Elevation Acute Coronary Syndrome (from the International Trial SYNERGY)
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
General Cardiology in Portola Valley Portola Valley, CA
Portola Valley, CA
General Cardiology in Portola Valley
3260 Alpine Rd
Portola Valley , CA 94028
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(19 reviews)
He is Always Excellent
An excellent Doctor!...
Dr Mahaffey was not available. Believe I should have been notified of such before I kept the apt.
Dr. Mahaffey was excellent to listen to me and let me know what I need to do to improve my health. Prior to talk to him, I was check my pulse by the nurse and Dr. Nguyen. They just wanted to make sure they did not skip anything at all.
He’s very thorough and friendly.
Very nice, professional, and easy to talk too.
He is a competent and friendly doctor. Easy to talk with, and easy to understand when he explains test results with you.
He is an experienced professional with expertise in his area.
Also excellent! I had no previously seen a cardiologist, but if I were to need one again, I would return.
When asked if I had done research on issues I said I did. I told him what I had learned & he went on to as if he didn't even hear what I had to say.
Dr. Mahaffey and the fellow doctor were very attentive, caring and understanding.
Both doctors listened well & explained thoroughly, helped put my experience of a heart irregularity in perspective.
I LIKED Dr. Mahaffey - warm, friendly, clear, no problems at all.
Very good.
Excellent courtesy & respect in every aspect of my care! Thank you!
Good.
Dr. Mahaffey was great.
Dr. Mahaffey & fellow were very thorough in their findings, I feel very confident with their service.
Good.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records